



HHS Public Access

Author manuscript

Nat Rev Nephrol. Author manuscript; available in PMC 2023 June 19.

Published in final edited form as:

Nat Rev Nephrol. 2023 February ; 19(2): 123–138. doi:10.1038/s41581-022-00643-3.

Oxalate homeostasis

Theresa Ermer¹, Lama Nazzal², Maria Clarissa Tio³, Sushrut Waikar⁴, Peter S. Aronson⁵, Felix Knauf^{5,6,✉}

¹Department of Surgery, Division of Thoracic Surgery, Yale School of Medicine, New Haven, CT, USA.

²Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.

³Division of Nephrology, University of Mississippi Medical Center, Jackson, MS, USA.

⁴Department of Medicine, Section of Nephrology, Boston University, Boston, MA, USA.

⁵Department of Internal Medicine, Section of Nephrology, Yale School of Medicine, New Haven, CT, USA.

⁶Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.

Abstract

Oxalate homeostasis is maintained through a delicate balance between endogenous sources, exogenous supply and excretion from the body. Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adequate oxalate excretion to maintain oxalate homeostasis. In patients with primary or secondary hyperoxaluria, nephrolithiasis, acute or chronic oxalate nephropathy, or chronic kidney disease irrespective of aetiology, one or more of these elements are disrupted. The consequent impairment in oxalate homeostasis can trigger localized and systemic inflammation, progressive kidney disease and cardiovascular complications, including sudden cardiac death. Although kidney replacement therapy is the standard method for controlling elevated plasma oxalate concentrations in patients with kidney failure requiring dialysis, more research is needed to define effective elimination strategies at earlier stages of kidney disease. Beyond well-known interventions (such as dietary modifications), novel therapeutics (such as small interfering RNA gene silencers, recombinant oxalate-degrading enzymes and oxalate-degrading bacterial strains) hold promise to improve the outlook of patients with oxalate-related diseases. In addition, experimental evidence suggests that anti-inflammatory medications might represent another approach to mitigating or resolving oxalate-induced conditions.

Reprints and permissions information is available at www.nature.com/reprints.

✉ Correspondence should be addressed to Felix Knauf. felix.knauf@charite.de.

Author contributions

All authors researched data for the article, made substantial contributions to discussions of the content, and wrote, reviewed or edited the manuscript before submission.

Introduction

Oxalate, a seemingly inconspicuous dicarboxylic acid, is one of the 20 uraemic toxins with the highest relative increase in uraemia¹. Oxalate homeostasis is maintained by a complex interplay of supply, metabolic pathways and excretion (Fig. 1). Consequently, oxalate homeostasis can be disturbed by numerous factors. Genetic mutations can disrupt endogenous oxalate biosynthesis and transport, whereas dietary and microbial factors as well as gastrointestinal pathologies can affect oxalate absorption. Kidney disease can also impair the elimination of oxalate, thereby turning a harmless, low-concentration metabolite into a serious multisystemic threat that can affect nearly every organ and tissue in the body, including the cardiovascular system^{2–4}.

Increased serum or urine oxalate concentrations have been associated with progressive kidney disease^{5,6}, cardiovascular conditions^{2,3}, and cellular and systemic inflammation^{7–9}. A 2021 study also identified elevated serum oxalate concentrations as a novel risk factor for sudden cardiac death in patients receiving dialysis³. Novel translational research findings, for example, regarding the pathogenesis of atherosclerosis¹⁰, are currently helping to move the field from mere association to causation. Further discoveries about the pathophysiology of uraemic toxins such as oxalate might help reduce the still unacceptably high excess mortality of patients with kidney and cardiovascular disease. As new evidence on the clinical implications of excess oxalate accumulates, it is crucial to understand the basic principles governing oxalate homeostasis. New studies have, for example, further defined the crucial involvement of epithelial transport proteins and the gut microbiome in oxalate regulation^{11,12}.

In this Review, we will examine the pathways of oxalate in the body, highlighting core mechanistic steps and their clinical implications. This information will provide the groundwork for a discussion of the pathophysiological consequences of oxalate accumulation. We will also consider novel interventional, pharmacological and microbial approaches to prevent, mitigate or resolve oxalate-related conditions that affect the kidney, heart and other organs.

Oxalate sources and metabolism

Oxalate is the ionized conjugate base of oxalic acid, which is the simplest dicarboxylic acid^{13,14}. Oxalate is either produced endogenously as a metabolic end-product or can be ingested as a component of numerous foods, drinks or chemicals (Fig. 1a). Healthy individuals typically maintain a plasma oxalate concentration of 1–5 μM . Of note, the 'normal' plasma oxalate range can vary depending on the measurement method; for example, one study reported that concentrations up to 11 μM were normal^{15–17}.

Hepatic oxalate biosynthesis has been estimated to contribute 50–80% of total body oxalate levels, based on the measurement of the relative contribution of varying dietary oxalate intake on urinary oxalate levels¹⁸. Numerous molecules derived from amino acid and carbohydrate metabolism have been identified or suggested to be oxalate precursors (Fig. 2 and Table 1). For example, hydroxyproline, which derives from collagen catabolism,

contributes an estimated 15% to urinary oxalate in healthy individuals¹⁹. Glycolate is another well-established oxalate precursor and has been estimated to contribute to <3% of oxalogenesis via peroxisomal metabolism²⁰. An ongoing non-randomized clinical trial will use ¹³C₂-glycolate infusion to estimate the contribution of glycolate to oxalate formation in healthy individuals²¹. Of note, although glycolate is thought to be present in most cells, its biological role is incompletely characterized²². Glyoxal is a product of carbohydrate autoxidation, lipid peroxidation and protein glycation that is primarily detoxified to glycolate by the glyoxalase system^{23,24}. Oxalate synthesis from glyoxal in human erythrocytes and hepatocytes has been reported in vitro^{24,25}, although a subsequent study suggested that this pathway might be of minor relevance in vivo²⁶. Glyoxal was also proposed as the missing link between nephrolithiasis, hyperoxaluria and diabetes given that both glyoxal and oxalate excretion are elevated in patients with diabetes^{23,27}. Finally, glycine is a small amino acid estimated to contribute <5% to urinary oxalate under physiological conditions²⁸ (Fig. 2). Other amino acids, such as tryptophan, tyrosine and phenylalanine, are also potential oxalate precursors but are estimated to make only minor contributions to endogenous oxalate²⁸.

Although endogenous oxalogenesis is incompletely understood, many pathways converge in glyoxylate as the immediate oxalate precursor^{19,25} (Fig. 2). In a physiologically balanced state, glyoxylate is enzymatically converted to either glycine or glycolate. However, excess glyoxylate is converted into oxalate by liver-specific lactate dehydrogenase A (LDHA)^{19,20}. Exogenous substances that can be metabolized to oxalate include large quantities of vitamin C supplements or of the colourless toxic alcohol ethylene glycol²⁹. Notably, the measurement of oxalate in biological fluids in vitro is complicated by the non-enzymatic conversion of ascorbic acid to oxalate under non-acidic conditions³⁰. This process might also contribute to the elevated plasma oxalate concentrations measured in patients who receive vitamin C supplements³⁰. Ethylene glycol, which is often used as antifreeze owing to its low freezing point, is most commonly ingested with suicidal intent, as a cheap substitute for alcohol or accidentally by children³¹. After rapid gastrointestinal absorption, the majority of ethylene glycol is metabolized to glycolaldehyde by alcohol dehydrogenase in the liver and then converted to oxalate through several oxidative steps³¹ (Fig. 2). Extremely elevated plasma and urine concentrations of ethylene glycol and of its metabolites glycolic acid and lactic acid result in severe anion-gap acidosis as well as neurological, cardiopulmonary and kidney impairment³¹.

Despite a low bioavailability of only 5–15%^{32,33}, dietary oxalate is estimated to contribute to 20–50% of total body oxalate^{18,34} (Table 1). Oxalate ingestion varies widely across culinary styles and diets in different regions of the world^{29,35}. The typical intake of 100–200 mg/day (with a wide range) in Western diets is presumed to be harmless in patients with normal kidney function^{29,36}. However, numerous studies have reported cases of acute nephropathy induced by the intake of extreme quantities of oxalate-rich foods (for example, starfruit)²⁹. Transit studies suggest that physiological oxalate absorption mainly takes place in the small intestine (and, to a smaller extent, in the stomach and colon) and is modified by the presence of other faecal components³⁷. Oxalate is an ionized conjugate base and is therefore highly susceptible to complexation with divalent cations such as Mg²⁺ and Ca²⁺, which bind oxalate in the faecal mass and reduce intestinal absorption^{14,37}.

Based on radioisotope-labelled oxalate infusion studies, >90% of oxalate is estimated to be eliminated via the kidney, unchanged^{32,38,39}. A physiological oxalate excretion of 10–40 mg/day (0.1–0.45 mmol/day) is maintained by a combination of glomerular filtration and net tubular secretion (mainly in the proximal tubule)^{33,34,40}. Only a small fraction of endogenous oxalate is excreted faecally³⁴, but enteric oxalate secretion is upregulated in murine chronic kidney disease (CKD) models, which might help prevent hyperoxalaemia^{11,41,42}.

Epithelial oxalate handling

As discussed earlier, plasma oxalate derives from metabolic production (mainly in the liver) and net gastrointestinal absorption of the dietary oxalate that is ingested under normal conditions^{14,37,43}. When kidney function is normal, oxalate is mainly excreted via the kidney through glomerular filtration and net tubular secretion^{14,37,43}. Thus, steady-state urinary oxalate excretion is in balance with the sum of metabolic oxalate production and net gastrointestinal absorption of dietary oxalate.

Epithelial transport of oxalate mediates its absorption and secretion, and several approaches have been used to characterize the transport pathways involved. For example, studies using membrane vesicles from kidney or intestine identified apical and basolateral membrane anion exchange activities through which oxalate can be reversibly exchanged with anions such as Cl^- , OH^- , HCO_3^- , sulfate and formate^{44–50}. Subsequently, cloned transporters from the solute carrier family 26 (SLC26) and SLC4 were found to mediate oxalate transport by some of the same modes of anion exchange. Specifically, functional expression of SLC26 member 1 (SLC26A1), SLC26A2 and SLC26A6 in *Xenopus* oocytes revealed that each solute carrier is capable of mediating the uptake or efflux of oxalate at high rates above baseline^{51–53}. Functional expression studies also reported detectable oxalate transport through SLC26A3, SLC26A5, SLC26A7, SLC26A8, SLC26A9 and SLC26A11 (refs.^{54–57}); SLC4A1 (also known as AE1) and SLC4A2 (also known as AE2) could also mediate oxalate transport^{58,59}. Of note, determining the physiological roles of these transporters in transepithelial oxalate transport and oxalate homeostasis in vivo has been challenging but studies with knockout mice have provided some insights.

Gastrointestinal tract

Ingested oxalate is absorbed in multiple portions of the gastrointestinal tract, including the stomach, small intestine and large intestine^{14,37,43}. Importantly, this absorption depends on its availability in soluble form because the formation of insoluble oxalate–calcium complexes blocks oxalate absorption^{14,37,43}. Oxalate absorption in the gastrointestinal tract is largely passive (driven by the lumen-to-basolateral concentration gradient) and correlates positively with the amount of soluble oxalate ingested³⁷. Transcellular absorption of oxalate in the stomach due to non-ionic diffusion across the apical membrane (driven by the extreme luminal acidity) is possible but, in the intestine, absorption seems to be predominantly paracellular given that the transepithelial oxalate permeability was similar to that of mannitol, which is a marker of paracellular permeability, across different segments of mouse intestine⁶⁰. However, the finding that net oxalate absorption occurs

in the absence of a passive driving force in studies of mouse ileum and large intestine suggests that transcellular absorption can also occur⁶¹ (Fig. 3). Moreover, oxalate absorptive fluxes were reduced in tissues from *Slc26a3*-null mice, which correlated with a reduced urinary oxalate excretion compared with that of wild-type mice⁶¹. Similarly, in wild-type mice with hyperoxaluria induced by an oral oxalate load, a small-molecule inhibitor of SLC26A3 significantly decreased oxalate absorption in the colon and greatly reduced urinary oxalate and oxalate nephropathy in response to oxalate feeding⁶². These studies not only demonstrated transcellular oxalate absorption but also demonstrated that it is, at least partly, dependent on the expression and activity of the apical membrane transporter SLC26A3. However, although functional expression studies of SLC26A3 demonstrated robust activity as a Cl^- - HCO_3^- exchanger⁶³, the ability of SLC26A3 cloned from multiple species (including humans) to transport oxalate was modest at best^{54,57,63,64}. These findings suggest that SLC26A3 might only contribute to oxalate absorption as a consequence of interactions with other transporters that are present in native tissue but that are not co-expressed with SLC26A3 in the reported functional expression studies.

Transcellular oxalate secretion in multiple intestinal segments opposes oxalate absorption³⁷. The importance of oxalate secretion in limiting net oxalate absorption has been most clearly demonstrated in mouse small intestine. The apical membrane oxalate transporter SLC26A6, which is expressed in the kidneys, pancreas and small intestine, has robust activity as a Cl^- -oxalate exchanger and would therefore be predicted to mediate oxalate efflux across cell membranes^{51,52,65}. Accordingly, net oxalate secretion in the duodenum and ileum of *Slc26a6*-knockout mice was greatly reduced compared with that of wild-type mice^{66,67}. Moreover, *Slc26a6*-null mice had hyperoxalaemia, which led to hyperoxaluria and urolithiasis; the development of urolithiasis was mouse-strain dependent^{66,67}. Removal of oxalate from the diet greatly reduced both hyperoxalaemia and hyperoxaluria in *Slc26a6*-null mice, indicating that the source of excess urinary oxalate was predominantly dietary⁶⁷. These findings support a role for SLC26A6 in back-secreting oxalate that is passively absorbed through tight junctions (Fig. 3). Moreover, a 2021 study suggests that short-chain fatty acids can reduce urinary oxalate levels by upregulating SLC26A6 (ref.⁶⁸). In a mouse model of CKD¹¹, faecal oxalate excretion increased following induction of CKD, suggesting that intestinal oxalate secretion might be enhanced in response to reduced kidney excretion, yet this increase was absent in *Slc26a6*-null mice, in which CKD-induced hyperoxalaemia was exacerbated compared with wild-type mice¹¹. Of note, epithelial oxalate secretion can also occur in the mouse large intestine in the absence of SLC26A6, indicating the presence of alternative pathways for apical membrane oxalate secretion, at least in this tissue⁶⁹. The relevance of intestinal SLC26A6 expression to oxalate homeostasis in humans is thus far only anecdotal. In a patient with subclinical coeliac disease and without fat malabsorption, hyperoxaluria correlated with a markedly reduced expression of SLC26A6 in the small intestine⁷⁰ whereas, in another patient, enteric hyperoxaluria and nephrolithiasis were associated with a dominant-negative *SLC26A6* mutation⁷¹. Knockout mice studies also demonstrated a role for SLC26A6 in epithelial oxalate secretion in the salivary gland⁷².

SLC26A1 is a basolateral sulfate- HCO_3^- -oxalate anion exchanger that is expressed in several tissues including liver, kidney and intestine^{52,73-77}. The initial report that *Slc26a1*-null mice had hyperoxalaemia, hyperoxaluria and crystal deposition in the kidneys (similar

to the phenotype of *Slc26a6*-null mice) suggested comparable participation of SLC26A1 and SLC26A6 in intestinal oxalate secretion⁷⁸. However, subsequent studies found that knockout of *Slc26a1* did not impair intestinal oxalate secretion^{79,80} but rather reduced urinary oxalate excretion⁸⁰. Biallelic *SLC26A1* mutations that impaired the transport function (assayed as sulfate flux) were identified in two patients with calcium oxalate nephrolithiasis, although only one of the patients had hyperoxaluria (mild)⁸¹. Consequently, whether loss of function of SLC26A1 can cause substantial hyperoxaluria owing to defective intestinal oxalate secretion remains highly uncertain.

Liver

In addition to variable expression along the gastrointestinal tract, SLC26A6 and SLC26A1 are both expressed in the liver and proximal tubule^{73,74,82–85}. In the liver, the kinetic properties of basolateral SLC26A1 indicate that it is a strong candidate mediator of the efflux of metabolically produced oxalate into the plasma pool⁷⁷, whereas apical SLC26A6 might contribute to the reported biliary excretion of oxalate⁸⁶. However, direct evidence for a role of these transporters in mediating oxalate transport in hepatocytes is lacking.

Kidneys

In the kidneys, oxalate is filtered and then undergoes passive absorption and active secretion in the proximal tubule, resulting in net secretion^{40,87}. Net kidney oxalate secretion is dependent on SLC26A6 as the fractional excretion of oxalate decreased from >1 in wild-type mice to <1 in *Slc26a6*-null mice⁸⁸. A defect in kidney oxalate secretion in *Slc26a6*-null mice would therefore be expected to lower urinary oxalate. However, *Slc26a6*-null mice have hyperoxaluria, suggesting that the aforementioned defect in intestinal oxalate secretion leading to enhanced net oxalate absorption causes sufficient hyperoxalaemia to result in hyperoxaluria even when urinary oxalate secretion is reduced. SLC26A1 is a plausible candidate to mediate basolateral membrane influx of oxalate in combination with apical SLC26A6 to accomplish oxalate secretion in the proximal tubule. However, the kinetic properties of SLC26A1 might preclude it from mediating a substantial influx of oxalate under physiological conditions⁷⁷. Specifically, based on the relative affinities for HCO₃⁻ and oxalate compared with their plasma concentrations, SLC26A1 was predicted to predominantly mediate HCO₃⁻ rather than oxalate influx in exchange for intracellular sulfate in the proximal tubule⁷⁷. No direct evidence of a role for SLC26A1 in mediating oxalate secretion by the proximal tubule is yet available, although the reduced urinary oxalate excretion observed in mice with global knockout of *Slc26a1* (ref.⁸⁰) could hint at a role in kidney oxalate secretion.

Interestingly, human studies demonstrated that, under fasting conditions, fractional excretion of oxalate is ~1, indicating little or no net secretion, although appreciable and rapid net oxalate secretion occurs after ingestion of an oxalate load⁸⁹. Similarly, substantial net oxalate secretion is observed in patients with elevated plasma oxalate owing to primary hyperoxaluria (PH) but not in patients who form stones without PH⁹⁰. The mechanisms underlying the upregulation of kidney oxalate secretion in response to acute or chronic oxalate loads remain to be defined. Another aspect of kidney oxalate handling that is incompletely understood is transepithelial transport beyond the proximal tubule.

For example, active net absorption of oxalate has been described across the kidney papillary epithelium⁹¹. Although this process might not substantially modify urinary oxalate excretion, it might modulate the local interstitial concentration of oxalate and thus affect crystal formation⁹¹.

Of note, independently of its role as an oxalate transporter, SLC26A6 might also be an important modifier of the risk of stone formation owing to its ability to interact with and inhibit the activity of the citrate transporter NADC1 (also known as SLC13A2)⁹². Knockout of *Slc26a6* leads to increased activity of NADC1, greater reabsorption of filtered citrate, reduced excretion of urinary citrate and greater risk of calcium nephrolithiasis⁹².

Role of the microbiome in oxalate homeostasis

Trillions of bacteria colonize the human gut and are involved in diverse functions, including the metabolism of dietary components^{93,94}. These bacteria are increasingly recognized to make important contributions to health and disease. Humans and other mammals lack the enzymes to metabolize oxalate and therefore rely on bacterial degradation to reduce intestinal oxalate, potentially reducing its absorption⁹⁵. *Oxalobacter formigenes* is a specialist oxalate degrader and induces colonic oxalate secretion^{96–98}. Epidemiological data have linked antibiotic use with an increase in the incidence of kidney stones^{99,100}, and disturbance of oxalate-degrading microbiota might be a contributing factor¹⁰¹.

Numerous oxalate-degrading microbes have been identified in vitro, but the relative importance of each species in vivo is debated¹⁰². A 2021 systematic analysis used high-throughput metagenomic and metatranscriptomic data to investigate bacterial oxalate degradation in vivo. The study showed that the human gut microbiota in healthy adults comprises a diverse community that actively transcribes oxalate-degrading genes¹². In healthy individuals, oxalate degradation is primarily performed by *O. formigenes*, which represents the largest reservoir of oxalate-metabolizing genes at the transcriptional level, greater than all other oxalate-degrading organisms combined, including *Escherichia coli*, *Bifidobacterium* spp. and *Lactobacillus* spp.¹² (Fig. 4).

Most studies linking microbial oxalate metabolism and disease were performed by comparing the gut microbiome of individuals who form kidney stones to that of healthy individuals^{103–105}. For example, analysis of stool cultures showed that the prevalence of *O. formigenes* was lower in individuals who form stones than in healthy individuals¹⁰⁶, but this finding was not consistent with subsequent studies that used microbiome sequencing data^{107,108}. Comparing the gut microbiome of individuals who form stones with that of cohabitating healthy adults revealed that healthy individuals had a more extensive microbial network with a higher abundance of connected species centred around *O. formigenes*, which suggests that they might have a greater capacity for microorganism-driven oxalate metabolism¹⁰⁸. Levels of bacterial genes involved in oxalate degradation were also significantly lower in the microbiome of individuals who form stones, which correlated inversely with 24-h oxalate excretion. Similarly, the cumulative abundance of oxalate-degrading bacteria correlated inversely with urinary oxalate¹⁰³. One study also reported that oxalate-degrading bacteria of three taxa — *Enterococcus faecalis*, *Enterococcus faecium*

and *Bifidobacterium animalis* — were less abundant in children with kidney stones than in healthy children¹⁰⁵. By contrast, an earlier study showed that patients with hyperoxaluria and kidney stones had a selective enrichment of oxalate-metabolizing bacterial species compared with healthy controls¹⁰⁴. More translational and clinical studies are needed to establish the causal relationship between the abundance and function of oxalate-degrading microbiota and urinary oxalate.

Dysregulated oxalate homeostasis

Dysfunction in key steps of physiological oxalate homeostasis can lead to the development of different types of primary and secondary hyperoxaluria (Figs. 1b and 2). Hyperoxaluria is defined as a urinary oxalate excretion of >40–45 mg/day (0.45–0.5 mmol/day), which is associated with various systemic manifestations^{34,109}.

Primary hyperoxaluria

PH comprises autosomal recessive inherited enzyme deficiencies that result in increased hepatic oxalogenesis (Table 2 and Fig. 2; reviewed in ref.¹¹⁰). The diagnosis of PH is primarily based on clinical presentation, including elevated oxalate concentrations in plasma and urine, and can be confirmed with genetic analyses^{110–113}. The most common manifestations of PH include urolithiasis, nephrocalcinosis and urinary tract infections^{111,112,114}. The carrier frequency in the population is estimated at 1:70, and estimates of disease prevalence range between 1:58,000 and <3:1,000,000 (ref.¹¹³). PH type 1 (PH1) is characterized by a deficiency of alanine–glyoxylate aminotransferase (AGT; encoded by *AGXT*). More than 200 different *AGXT* mutations have been identified, with a highly variable genotype–phenotype correlation (see the Human Gene Mutation Database)¹¹⁰. A 2022 study used non-canonical splicing site and copy number variant sequencing to improve the diagnostic accuracy from 26% to 35% in patients with suspected PH¹¹⁵. Of note, another study implemented bioinformatics to identify the microRNA miR-4660, which repressed AGT activity in a subgroup of patients with mutation-negative oxalosis¹¹⁶. Several mutations lead to protein aggregation and mitochondrial mistrafficking of AGT (in humans, AGT needs to be peroxisomal to function properly)¹¹⁷, which results in decreased or diminished enzyme activity^{118–120}. A 2021 report suggested that lack of protein dimerization might be one of the mechanisms underlying AGT mistrafficking¹²¹.

PH type 2 (PH2) accounts for approximately 7.9–10% of PH cases and results from mutations in *GRHPR*, which encodes the enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). This enzyme detoxifies glyoxylate to glycolate in the cytosol and mitochondria of hepatocytes^{111,112}. In GRHPR deficiency, glyoxylate and hydroxypyruvate accumulate and are subsequently converted to oxalate and L-glycerate by hepatic LDHA¹¹². At least 39 *GRHPR* mutations have been described¹¹². PH type 3 (PH3) is caused by a mutation in the gene encoding 4-hydroxy-2-oxoglutarate aldolase type 1 (*HOGA1*), which is primarily expressed in hepatocyte mitochondria, and accounts for 8.4–17% of PH cases¹¹¹. *HOGA1* catalyses the last step of hydroxyproline metabolism by converting 4-hydroxy-2-oxoglutarate (HOG) into glyoxylate and pyruvate; in *HOGA1* deficiency, HOG accumulation has been reported to inhibit GRHPR, resulting in increased oxalate

production¹⁹. A 2021 report described at least 37 *HOGAI* mutations¹¹¹. The age of disease onset was reportedly earlier in PH3 than in PH2 (ref.¹¹³), but several studies report a median age of onset <10 years of age for all three PH types, with a range reaching into late adulthood^{4,111–113} (Table 2).

The natural history of PH evolves in two phases and their exact timelines depend on the severity and type of the underlying mutation. In the first phase, increased oxalate synthesis is compensated by hyperoxaluria that can reach extremes of up to 1–2 mmol/1.73 m²/day and eventually results in oxalate deposition in the kidney and progressive kidney damage. The second phase unravels as kidney function declines, oxalate excretion becomes insufficient and systemic oxalate deposition ensues, which leads to secondary organ damage⁴. Although urinary oxalate concentrations have been suggested to correlate positively with PH progression, the most common PH1-causing *AGXT* mutation, G170R, typically correlates with less severe progression of kidney disease, compared with other PH1-driving *AGXT* mutations. This difference might be partially explained by the ability to reduce enzyme mistargeting in the G170R genotype through treatment with the cofactor pyridoxine, also known as vitamin B6 (only a few other PH1-causing mutations, such as *AGXT*^{F152I}, respond to pyridoxine)¹¹³. Of note, in the largest study of PH2 to date, the progression of CKD was not associated with genotype or urinary oxalate excretion in an age-corrected analysis¹¹². In this study, patients with PH2 were also less likely than patients with PH1 to present with CKD stage V at diagnosis or before 15 years of age¹¹². In the largest study to date of patients with PH3, PH3 genotype and phenotype did not correlate, and urinary oxalate excretion was not significantly different between vitamin B6-non-responsive PH1, PH2 and PH3 (ref.¹¹¹). Although kidney failure due to PH3 has been reported¹¹³, most studies describe milder kidney disease in patients with PH3 than in those with PH1 or PH2. However, these data might be biased owing to the scarcity of long-term outcome monitoring data and the low penetrance of *HOGAI* mutations¹¹¹.

Secondary hyperoxaluria

Secondary hyperoxalurias are broadly classified as enteric or dietary²⁹. The most common aetiologies of enteric hyperoxaluria are Roux-en-Y gastric bypass and pancreatic insufficiency¹²²; others include malabsorptive conditions, such as short bowel syndrome, coeliac disease, Crohn's disease and cystic fibrosis, or the use of medications that interfere with intestinal oxalate absorption such as octreotide, which is a somatostatin analogue, or orlistat, which is a lipase inhibitor³⁶. Dietary hyperoxaluria is most often caused by excessive intake of vitamin C or oxalate (discussed above)¹²².

All types of hyperoxaluria are characterized by three histopathological hallmarks: calcium oxalate crystal deposition, damage to the tubular epithelium and interstitial alterations in the kidney²⁹. However, these patterns might differ between different aetiologies of oxalate nephropathy. For example, in one study, patients with enteric hyperoxaluria were more likely to have tubulointerstitial atrophy and fibrosis, whereas those with non-enteric hyperoxaluria had more pronounced tubular crystal accumulation and interstitial inflammation¹²². The authors hypothesized that the severity of the kidney outcomes might depend on the latency period following oxalate exposure. However, the mechanisms underlying these

differences in the clinical manifestations of enteric and non-enteric hyperoxaluria are still unknown. In vivo findings suggest that crystal deposition is crucial to hyperoxaluria-induced inflammation¹²³.

Chronic kidney disease

In PH, increased endogenous hepatic synthesis of oxalate can lead to extreme plasma oxalate concentrations ranging from 80 μM to 125 μM in advanced stages of disease¹²⁴. In people with common forms of CKD who do not have PH, plasma or serum oxalate is elevated owing to kidney impairment, especially in patients with kidney failure undergoing dialysis. Nonetheless, plasma or serum oxalate levels in these patients are not as high as those observed in patients with PH, except in patients with Crohn's disease and ileocecal resections that are treated with maintenance haemodialysis^{124–126}. In these patients, serum oxalate levels correlate with calcium oxalate supersaturation in serum samples and, in certain cases, might reach the serum calcium oxalate supersaturation threshold of 30 μM ^{124,125} (Fig. 1b). Although high plasma oxalate was associated with kidney function decline in primary hyperoxaluria¹²⁷, data on plasma oxalate and outcomes in more common forms of CKD are currently limited. Nonetheless, although classically described as a risk factor for nephrolithiasis and acute kidney injury owing to intratubular crystal obstruction, the role of oxalate in the pathogenesis of CKD has been further defined in the past few years. Mice fed a diet high in oxalate developed a reproducible CKD phenotype characterized by hypertension, hyperkalaemia, metabolic acidosis, anaemia and hyperphosphataemia; kidney histopathology revealed fibrosis, tubular injury, atubular glomeruli and inflammation¹²⁸. Epidemiological studies also showed that higher urinary and plasma oxalate levels might be associated with adverse outcomes in kidney disease. A prospective study of adults with common forms of CKD (Chronic Renal Insufficiency Cohort) in the USA showed an independent association between 24-h urinary oxalate excretion and both CKD progression and kidney failure⁶. Participants in the highest quintile of urinary oxalate excretion had a 33% increased risk of CKD progression and 45% increased risk of kidney failure; 24-h urinary oxalate excretion was also positively associated with greater levels of proteinuria and lower estimated glomerular filtration rate (eGFR)⁶. Importantly, plasma oxalate levels can be significantly elevated in patients with kidney failure on dialysis because dialysis cannot completely compensate for lost kidney excretion. In a post-hoc analysis of data from a randomized controlled study of patients with diabetes receiving dialysis in Germany, the highest quartile of blood oxalate level was associated with a 40% increased risk of combined cardiovascular events (composite of death from cardiac causes, fatal or non-fatal stroke, or non-fatal myocardial infarction)³. Blood oxalate levels were also significantly associated with sudden cardiac death in secondary analyses.

The role of oxalate as a biomarker in kidney transplant recipients is also unclear. Urinary oxalate excretion was not associated with graft survival¹²⁹, but the presence of calcium oxalate deposits in allograft biopsy samples might be associated with delayed graft function and decline in allograft function^{130,131}. In 167 kidney transplant recipients followed for 15 years who had plasma oxalate measured 10 weeks after transplantation, plasma levels in the upper quartile were associated with lower long-term patient survival and graft loss; however, these associations were not significant when examining death-censored graft loss¹³².

Metabolic diseases

Several metabolic diseases are associated with mild hyperoxaluria. For example, individuals with obesity have a high incidence of nephrolithiasis and hyperoxaluria, which correlates with decreased eGFR and increased risk of CKD¹³³. One potential culprit is the pro-inflammatory effect of obesity. Obese mice had a 3.3-fold increase in urinary oxalate excretion (adjusted for creatinine) compared with lean control mice; this increase was accompanied by a significant reduction in intestinal oxalate secretion. This change in secretion might be due to reduced expression of SLC26A6 in obese mice compared with lean mice¹³⁴. In vitro, pro-inflammatory cytokines suppress *Slc26a6* mRNA and protein expression¹³⁴. Another group identified glyoxylate pathway modifications in the hepatocytes of obese mice that led to the hypermethylation and downregulation of *Agxt*. These changes resulted in a significant increase in hepatic oxalogenesis after hydroxyproline challenge¹³⁵. Moreover, the pathophysiological overlap between oxalate excretion and diabetes is notable. Individuals with diabetes have an 11% increase in urinary oxalate excretion compared with individuals without diabetes⁶, which might be partly attributable to elevated concentrations of the oxalate precursors glyoxal and glyoxylate²⁷. Of note, the presence of diabetes was associated with a 44% increase in the risk of a 50% reduction in eGFR or kidney failure among patients with urinary oxalate excretion of ≥ 16.2 mg/day compared with those with urinary oxalate excretion of <16.2 mg/day⁶.

Cellular effects of excess oxalate

As discussed earlier, oxalate can form complexes with positively charged minerals. These complexes can grow in size and form oxalate kidney stones that obstruct urinary flow and cause kidney damage¹³³. In addition, oxalate can affect cellular function directly. In vitro, oxalate inhibits the proliferation of kidney epithelial cells, stimulates fibrotic transformation and calcification, and induces cell death^{128,136}. Oxalate might also promote epithelial-to-mesenchymal transformation¹³⁷. Incubating mouse inner medullary collecting duct cells with oxalate increased expression of mesenchymal markers such as α -smooth muscle actin (also known as aortic smooth muscle actin) and reduced E-cadherin expression¹³⁸. Moreover, oxalate activates nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in kidney epithelial cells and triggers the release of reactive oxygen species, which promotes oxidative stress¹³⁹, and has been associated with reduced glutathione and impaired mitochondrial function¹⁴⁰.

In addition to the effect of oxalate on epithelial cells, several studies have suggested that oxalate crystals activate inflammatory cells¹⁴¹. For example, oxalate crystals stimulated dendritic cells and macrophages to synthesize and release IL-1 β via activation of the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome^{5,9}. Moreover, exposure of human monocytes to a low dose of oxalate crystals disrupted mitochondrial function¹⁴². The investigators hypothesized that these biological events might predispose to recurrent stone formation. A subsequent study revealed that macrophages treated with oxalate also had decreased cellular bioenergetics, mitochondrial complex I and IV activity, and ATP levels compared with control cells¹⁴³. These cells had

impaired metabolism, redox homeostasis and cytokine signalling, which compromised their antibacterial response in vitro and increased the risk of bacterial infection¹⁴³.

A 2021 study demonstrated that the glycine-to-oxalate ratio in blood is lower in both patients and mice with atherosclerosis than in controls¹⁰. This effect was due to suppressed activity of AGT, similar to what is observed in patients with PH1. Mice deficient for AGT and apolipoprotein E (ApoE) had increased atherosclerosis compared with mice that were only deficient for ApoE, which was accompanied by the induction of hepatic pro-atherogenic pathways associated with increased inflammation (based on changes in cytokine and chemokine signalling). Macrophages from AGT-deficient mice exposed to oxalate also showed mitochondrial dysfunction and superoxide accumulation, which led to increased release of the pro-atherogenic CC chemokine ligand 5 (CCL5). The observed phenotype could be reversed with AGXT overexpression. One of the limitations of the study was the high concentration of oxalate used to stimulate macrophages; although non-cytotoxic, a concentration of 750 μM is still several times higher than that observed in the blood of patients, even in those with impaired kidney excretion. Nevertheless, this study suggests a mechanistic link between increased plasma oxalate and atherosclerosis.

These observations support previous studies suggesting that oxalate might promote atherosclerosis. In vitro, supraphysiological extracellular oxalate concentrations inhibit the proliferation and induce oxidative stress in endothelial cells^{8,144}. Moreover, the oxalate crystal-induced release of pro-inflammatory cytokine IL-1 α from monocytes has been associated with increased risk of atherosclerotic cardiovascular events in patients with acute myocardial infarction or CKD, possibly by promoting leukocyte–endothelial adhesion and inflammation through the expression of vascular cell adhesion molecule 1 on endothelial cells⁷. Importantly, future clinical studies will need to address whether oxalate concentrations observed in humans with hyperoxalaemia can have the same effects as exposure to supraphysiological amounts of oxalate in vitro.

Therapies for oxalate dysregulation

Many conservative treatment options are available for mild types of hyperoxaluria, including the hyperoxaluria observed in patients with nephrolithiasis. These therapeutic approaches are based on the prevention of urinary calcium oxalate crystallization and might be as simple as adequate hydration, which has proven useful for the prevention of kidney stones; hyperhydration is recommended in patients with PH1 (>3 l/1.73 m² body surface area/day)^{110,145,146}. In addition, a phase I trial of tolvaptan has shown promise in reducing urinary calcium oxalate, calcium phosphate and uric acid supersaturation by increasing urine volume¹⁴⁷. A similar effect was reported for thiazide diuretics, whose hypocalciuric and hypermagnesiuric properties might reduce calcium oxalate kidney stone formation¹⁴⁸. Citrate administration has also been suggested to prevent the formation of kidney stones^{149,150}. Moreover, a 2016 study showed that citrate and hydroxycitrate can dissolve calcium oxalate monohydrate crystals in vitro¹⁵⁰. Even at concentrations three times lower than that of the solute, citrate and hydroxycitrate adsorption to oxalate crystal surfaces led to the localized dissolution of calcium and oxalate ions with comparable efficacy¹⁵⁰. Of note, a 2022 report from a phase II clinical trial suggested that lemon juice

might be a viable alternative to pharmaceutical citrate formulations, which are frequently discontinued by patients owing to adverse gastrointestinal effects¹⁵¹.

Targeting oxalate absorption

In enteric hyperoxaluria, several therapeutic approaches are based on the binding of oxalate in the intestine to prevent hyperabsorption. As described earlier, the bioavailability of oxalate is influenced by gut health and the presence of different faecal components (for example, cations, fat or medication)^{14,36,37}. Consequently, direct supplementation of calcium and fat limitation (which has been reported to increase intestinal calcium–oxalate binding) might decrease oxalate hyperabsorption^{146,152}. Based on the same principle of limiting oxalate absorption, the bile acid-binding resin cholestyramine reduced colonic oxalate absorption in rats by blocking the binding of oxalate to bile acids and subsequent intestinal reabsorption but its efficacy was variable in humans¹⁵³. However, in a case study of a patient with short bowel syndrome, cholestyramine reduced both faecal fat and urinary oxalate excretion¹⁵⁴. Calcium-containing phosphate binders, which might promote the formation of calcium–oxalate complexes, have also been suggested as potential oxalate-lowering agents¹⁵⁵. However, current KDIGO guidelines recommend limiting the use of calcium-based phosphate binders in patients with CKD stages G3a–G5D owing to the increased mortality risk associated with these compounds compared with non-calcium-based phosphate binders¹⁵⁶. Following encouraging experimental results, the non-calcium-based phosphate binder lanthanum carbonate is currently being tested in a phase III trial in patients with secondary hyperoxaluria and nephrolithiasis¹⁵⁷. Treatment with the non-calcium phosphate binder sevelamer hydrochloride for 1 week also led to a non-significant reduction in urinary oxalate in an open-label study of patients with enteric hyperoxaluria¹⁵⁸. Of note, a 2021 quantum chemical study suggested that trivalent cations, such as Fe³⁺, Al³⁺ or La³⁺, rather than divalent cations as well as the chemical element neodymium, might be interesting oxalate-binding candidates for preclinical testing¹⁵⁹.

Microbiome-related therapies

The effect of microbiome manipulation on oxalate homeostasis using single organisms or bacterial communities has been evaluated extensively in animal models and a few human studies (Fig. 4). Consequently, several therapeutic formulations are based predominantly on the oxalate-degrading capacity of certain bacteria. In rodent models of hyperoxaluria, *O. formigenes* colonization consistently led to a reduction in urinary oxalate^{97,160}. In addition to oxalate degradation, *O. formigenes* produced a secretagogue, yet to be characterized, that induces oxalate secretion into the gut⁹⁷. However, although the *O. formigenes* derivatives OC3 and OC5 (lyophilized *O. formigenes* in enteric-coated capsules, the latter with a higher viable cell count) are well tolerated by humans, they had mixed efficacy in phase I–III trials^{161,162}.

Colonization with *Bifidobacterium* and *Lactobacillus* species also reduced urinary oxalate in animals^{97,163}. Oxadrop, which is a probiotic composed of *Lactobacillus acidophilus*, *Lactobacillus brevis*, *Streptococcus thermophilus* and *Bifidobacterium infantis*, resulted in a short-lived reduction in urinary oxalate in patients with enteric hyperoxaluria¹⁶⁴. Importantly, none of these trials evaluated bacterial viability in the gut following their

ingestion. Other bacterial strains currently being investigated in early-stage trials include Nov-001, UBLG-36 and SYN8802. Nov-001 is a therapeutically engineered microbial combination product that includes NB1000S, which is an oxalate-degrading bacterium, and NB2000P, a prebiotic control molecule used to control the abundance of NB1000S; a phase II trial is currently recruiting patients with enteric hyperoxaluria after an encouraging phase I study¹⁶⁵. UBLG-36, which is a *Lactobacillus paragasseri* strain, is highly effective in degrading oxalate in vitro¹⁶⁶. Finally, orally administered SYN8802, which is a synthetic oxalate-degrading *E. coli* Nissle strain, significantly reduced urinary oxalate in mice and non-human primates. In silico modelling based on human gastrointestinal physiology predicted that this strain could lower urinary oxalate by up to 71% in patients with enteric hyperoxaluria¹⁶⁷.

Whole microbial transfers have also been investigated as potential approaches to modulate oxalate metabolism. In rats, a faecal transplant from a mammalian herbivore whose whole microbiome community is adapted to degrading high amounts of dietary oxalate led to lower urinary and faecal oxalate levels compared with the ingestion of oxalate-degrading isolates¹⁶⁸; the decrease in urinary oxalate persisted for 9 months after the transfer¹⁶⁹. Similarly, a faecal transplant from conventional rats, which have a gut microbiome similar to that of humans, into germ-free mice reduced urinary oxalate¹⁷⁰. This transfer caused a reduction in SLC26A6 expression in the kidney and colon and increased expression in the caecum. To date, no studies have evaluated the effect of microbiome community transfer in humans.

Instead of administering bacterial strains, several investigators have attempted direct supplementation with oxalate decarboxylase (OxDC), which is the enzyme used by *O. formigenes* to degrade oxalate. A double-blind randomized controlled crossover trial of a proprietary OxDC in healthy individuals showed a 24% urinary oxalate reduction compared with placebo¹⁷¹. In a phase I trial, recombinant OxDC cloned from *Bacillus subtilis* significantly reduced urinary oxalate in patients with Roux-en-Y gastric bypass (mean 66.3 mg/day, standard deviation (SD) 28.0 mg/day at baseline; 44.5 mg/day, SD 23.7 mg/day at 4 weeks; $P=0.018$), but this reduction was not significant in patients with idiopathic calcium oxalate stone formation (43.2 mg/day, SD 5.9 mg/day at baseline; 32.3 mg/day, SD 3.2 mg/day at 4 weeks; $P=0.06$)¹⁷². Another OxDC formulation (ALLN-177) significantly reduced urinary oxalate excretion in patients with preserved kidney function, including a phase III trial in patients with enteric and idiopathic hyperoxaluria (urinary oxalate excretion for all participants 77.7 mg/day, SD 55.9 mg/day at baseline; 63.7 mg/day, SD 40.1 mg/day after 4 days of treatment; $P<0.05$)¹⁷³. In a pilot study of patients with CKD and severe enteric hyperoxaluria, ALLN-177 reduced plasma oxalate by 29% from baseline¹⁷⁴. However, a phase III study of ALLN-177 in patients with enteric hyperoxaluria over a 4-week period demonstrated that the reduction in urinary oxalate was only 14.3% greater than that achieved with placebo¹⁷⁵. Determining whether a modest lowering of urinary oxalate has a clinical benefit with regard to stone disease progression will require long-term follow-up studies.

Treatments for primary hyperoxaluria

Therapeutic options for primary hyperoxaluria have traditionally been scarce and the only curative option was combined liver and kidney transplantation¹¹⁰. Vitamin B6 supplementation reduces hepatic oxalate production by restoring AGT activity and reducing mitochondrial mistargeting in patients with PH1 owing to specific *AGXT* mutations, such as G170R or F152I, in vivo and clinically^{118–120}. More specifically, in vitro studies suggest that the monomer form of AGT is unstable and prone to misfolding and aggregation, which impedes peroxisomal transport; vitamin B6 promotes dimerization, which appears to stabilize the enzyme and may facilitate proper peroxisomal transport^{119,121}.

In vitamin B6-non-responsive PH1, therapeutic approaches aim to inhibit the key hepatic enzymes that produce oxalate (glycolate oxidase, also known as hydroxyacid oxidase, and LDHA), for example, by using RNA interference (reviewed in refs.^{110,176}). RNA interference is an innate mechanism of most eukaryotic cells that allows for sequence-specific inhibition of gene expression via non-coding double-stranded RNA fragments (20–25 bp long)^{177,178}. These small interfering RNAs (siRNAs) are recognized by an RNA-induced silencing complex, which induces degradation of the target mRNA^{177,178}. Exogenously synthesized siRNAs have been celebrated as a major therapeutic breakthrough that allows the potent repression of disease-causing genes. However, researchers are still improving chemical siRNA modifications to optimize organ-specific drug delivery and reduce off-target effects, including unintended immune stimulation^{177,178}.

siRNA-based Lumasiran is the first EMA-approved and FDA-approved PH1-specific treatment and must be administered subcutaneously¹¹⁰. This treatment silences the glycolate oxidase gene (*HAOI*) and was shown to reduce urinary oxalate by 64.1–70% compared with placebo in phase III trials of adults and children; the first results from another phase III trial (NCT04152200) are currently undergoing quality control^{179,180}. The resulting increase in plasma glycolate concentrations did not appear to be associated with adverse events¹⁷⁹, in contrast to the severe acidosis observed in patients with ethylene glycol poisoning leading to elevated plasma glycolate concentrations¹⁸¹. Case reports demonstrate tolerability and efficacy as early as the second week of life, and suggest that pre-treatment with Lumasiran might enable the use of isolated kidney transplantation (rather than combined with liver transplantation) in PH1 (refs.^{182,183}). Nedosiran, another subcutaneously administered siRNA-based drug, silences *LDHA* and was shown to reduce urinary oxalate excretion by 68% after multiple doses¹⁸⁴. The medication was also successfully used to reduce dialysis frequency and defer combined liver and kidney transplantation in a patient with PH1 (ref.¹⁸⁴); in a phase I study, nedosiran also normalized urinary oxalate excretion in one-third of patients with PH2 (ref.¹⁸⁵).

Gene editing has also been used to knock out *Hao1* and *Ldha* in animal studies. The CRISPR–Cas9 system was delivered by an adenovirus vector to knock out *Hao1* in *Agxt1*^{-/-} mice, which are used as a PH1 model; this treatment normalized urinary oxalate excretion and prevented nephrocalcinosis without toxicity¹⁸⁶. Administration of an *Ldha*-targeting adenovirus-coupled CRISPR–Cas9 system to rats with a PH1-causing *Agxt*^{D205N} mutation reduced LDHA expression by 50% and significantly lowered urinary oxalate excretion and kidney calcium oxalate deposits after an ethylene glycol challenge compared with

controls; the treatment also caused mild changes in hepatic glycolytic and triglyceride pathways¹⁸⁷. Another study of *Agxt1^{-/-}* mice treated with a single dose of an adenovirus-coupled CRISPR–Cas9 system reduced LDHA expression by >95% and reduced urine oxalate to levels similar to those of wild-type animals after ethylene glycol exposure without significant toxic off-target effects or hepatotoxicity¹⁸⁸. In a PH3 model (*Hoga1^{-/-}* mice), the same CRISPR–Cas9 cleavage vector system was slightly less effective than in the PH1 model but also induced a significant reduction in LDHA expression and urine oxalate levels were comparable to those of wild-type animals after hydroxyproline challenge¹⁸⁸. Of note, none of the mice in the PH3 model developed kidney damage upon hydroxyproline exposure (in contrast to PH1 mice challenged with ethylene glycol)¹⁸⁸. More research is needed to test the applicability of these findings and potential off-target effects in humans.

Immune modulation

Immune modulation is another potential approach for treating oxalate-related diseases. For example, inhibition of NLRP3 inflammasome activation might reduce cleavage of the pro-inflammatory cytokines IL-1 β and IL-18 via caspase 1 and inhibit inflammatory cell death (pyroptosis)¹⁸⁹. The microRNA miR-22-3p binds to NLRP3 as well as to long intergenic non-protein-coding RNA 339, which is highly upregulated in human kidney proximal epithelial cells treated with calcium oxalate monohydrate. This microRNA reduced calcium oxalate-induced inflammasome activation and pyroptosis in human kidney proximal epithelial cells in vitro¹⁹⁰. In a study of male hyperoxaluric rats, inhibition of the transient receptor potential vanilloid 1 channel, which functions upstream of NLRP3, mitigated reactive oxygen species-induced NLRP3 activation and calcium oxalate-induced nephropathy but did not reduce hyperoxaluria¹⁹¹. Other NLRP3 inhibitors with promising murine in vivo results include the diarylsulfonylurea-based CP-456773, which mitigates crystal-induced kidney fibrosis¹⁹².

Conclusions

An abundance of evidence supports a pathological role of excess oxalate when the balance between oxalate intake, production and excretion is disrupted. Overall, 50–80% of oxalate is endogenously produced and derived from amino acid and carbohydrate metabolism, whereas 20–50% derives from dietary intake and is absorbed predominantly in the small intestine. Epithelial transport of oxalate via anion exchange mediates oxalate absorption and secretion along the gastrointestinal tract, in the liver and in the kidneys, with SLC26A6 being the best-established oxalate transporter. The human gut harbours important microbial networks that help regulate oxalate levels, most notably the specialist oxalate degrader bacterium *O. formigenes*. Inherited enzyme defects that lead to increased endogenous oxalate production or increased intestinal absorption of oxalate observed in secondary hyperoxaluria can lead to oxalate nephropathy and kidney failure. Moreover, elevated urinary oxalate concentrations are associated with CKD progression, and increased plasma oxalate levels correlate with cardiovascular mortality in patients with kidney failure requiring dialysis. In addition, the presence of metabolic diseases, such as obesity and diabetes mellitus, might increase the risk of developing nephrolithiasis and hyperoxaluria or losing kidney function in the setting of high oxalate excretion. At a cellular level, oxalate inhibits proliferation, stimulates

fibrotic transformation and calcification, leads to the upregulation of pro-atherogenic and inflammatory pathways by promoting inflammasome activation and oxidative stress, and induces cell death.

Therapies for oxalate dysregulation aim to re-establish the physiological components necessary to maintain oxalate homeostasis (Table 3). Modulation of free oxalate availability in urine and the gut has been used as a successful strategy to mitigate nephrolithiasis and secondary hyperoxaluria. One promising approach on the horizon are allogeneic transfers of oxalate-degrading microbial communities to reduce urinary oxalate. By contrast, treatments for PH focus on restoring the function of enzymes involved in hepatic oxalogenesis such as AGT, for example, through vitamin B6 supplementation in select PH subtypes, or inhibition of oxalate-producing LDHA or glycolate oxidase through siRNAs or CRISPR–Cas9 technology. Finally, immune modulation is another potential approach to prevent and treat the severe consequences of oxalate-related diseases.

Further research is needed to better characterize the role and therapeutic potential of different transporters from the SLC26 anion exchanger family and microbial communities in maintaining oxalate homeostasis. Important open questions include the extent to which oxalate is causally involved in the progression of CKD and CKD-related cardiovascular disease as well as effective therapeutic strategies to achieve sustained lowering of oxalate concentrations. Additionally, more detailed studies of the inflammatory pathways through which oxalate exerts its detrimental effects will likely reveal new treatment options. Robust clinical studies are an essential next step to translate in vitro, in vivo and observational clinical findings into the human setting and leverage this knowledge for the prevention and treatment of oxalate-related conditions in clinical practice.

Acknowledgements

The work of F.K. was supported by the German Research Foundation (DFG) — KN1148/4-1 and Project-ID 394046635, SFB 1365.

Competing interests

F.K. reports personal fees from Allena, Oxthera, Sanofi, Fresenius Medical Care, Alnylam Pharmaceuticals, Advicenne, Medice and Zai, and grant support from Alnylam and Dicerna Pharmaceuticals. S.W. reports personal fees from Public Health Advocacy Institute, CVS, Roth Capital Partners, Kantum Pharma, Mallinckrodt, Wolters Kluwer, GE Health Care, GSK, Allena Pharmaceuticals, Mass Medical International, Barron and Budd (versus Fresenius), JNJ, Venbio, Strataca, Takeda, Cerus, Pfizer, Bunch and James, Harvard Clinical Research Institute (also known as Baim Institute for Clinical Research), Oxidien, Sironax, Metro Biotechnology, Biomarin, Bain and Regeneron. L.N. reports personal fees from Oxthera, Dicerna, Federation Bio, Allena, Novome and Synlogic. All other authors declare no competing interests.

References

1. Duranton F et al. Normal and pathologic concentrations of uremic toxins. *J. Am. Soc. Nephrol* 23, 1258–1270 (2012). [PubMed: 22626821]
2. Gulhan B et al. The relationship between serum oxalic acid, central hemodynamic parameters and colonization by *Oxalobacter formigenes* in hemodialysis patients. *Cardiorenal Med* 5, 164–174 (2015). [PubMed: 26195968]
3. Pfau A et al. High oxalate concentrations correlate with increased risk for sudden cardiac death in dialysis patients. *J. Am. Soc. Nephrol* 10.1681/ASN.2020121793 (2021).

4. Cochat P & Rumsby G Primary hyperoxaluria. *N. Engl. J. Med* 369, 649–658 (2013). [PubMed: 23944302]
5. Knauf F et al. NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. *Kidney Int* 84, 895–901 (2013). [PubMed: 23739234]
6. Waikar SS et al. Association of urinary oxalate excretion with the risk of chronic kidney disease progression. *JAMA Intern. Med* 179, 542–551 (2019).
7. Schunk SJ et al. Interleukin-1 α is a central regulator of leukocyte-endothelial adhesion in myocardial infarction and in chronic kidney disease. *Circulation* 144, 893–908 (2021). [PubMed: 34192892]
8. Sun K et al. Hyperoxalemia leads to oxidative stress in endothelial cells and mice with chronic kidney disease. *Kidney Blood Press. Res* 46, 377–386 (2021). [PubMed: 34044409]
9. Mulay SR et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1 β secretion. *J. Clin. Invest* 123, 236–246 (2013). [PubMed: 23221343]
10. Liu Y et al. Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis. *Cell Rep* 36, 109420 (2021). [PubMed: 34320345]
11. Neumeier LI et al. Enteric oxalate secretion mediated by Slc26a6 defends against hyperoxalemia in murine models of chronic kidney disease. *J. Am. Soc. Nephrol* 31, 1987–1995 (2020). [PubMed: 32660969]
12. Liu M et al. Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease. *eLife* 10.7554/eLife.63642 (2021).
13. Williams HE Oxalic acid and the hyperoxaluric syndromes. *Kidney Int* 13, 410–417 (1978). [PubMed: 351269]
14. Ermer T, Eckardt KU, Aronson PS & Knauf F Oxalate, inflammasome, and progression of kidney disease. *Curr. Opin. Nephrol. Hypertens* 25, 363–371 (2016). [PubMed: 27191349]
15. Ladwig PM, Liedtke RR, Larson TS & Lieske JC Sensitive spectrophotometric assay for plasma oxalate. *Clin. Chem* 51, 2377–2380 (2005). [PubMed: 16306102]
16. Porowski T et al. Reference values of plasma oxalate in children and adolescents. *Pediatr. Nephrol* 23, 1787–1794 (2008). [PubMed: 18581146]
17. Elgstoen KBP Liquid chromatography–tandem mass spectrometry method for routine measurement of oxalic acid in human plasma. *J. Chromatogr. B* 873, 31–36 (2008).
18. Holmes RP, Goodman HO & Assimos DG Contribution of dietary oxalate to urinary oxalate excretion. *Kidney Int* 59, 270–276 (2001). [PubMed: 11135080]
19. Fargue S et al. Hydroxyproline metabolism and oxalate synthesis in primary hyperoxaluria. *J. Am. Soc. Nephrol* 29, 1615–1623 (2018). [PubMed: 29588429]
20. Garrelfs S et al. Endogenous oxalate production in primary hyperoxaluria type 1 patients. *J. Am. Soc. Nephrol* 22, 3175–3186 (2021).
21. US National Library of Medicine. [ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT04437225](https://clinicaltrials.gov/ct2/show/study/NCT04437225) (2020).
22. Knight J, Hinsdale M & Holmes R Glycolate and 2-phosphoglycolate content of tissues measured by ion chromatography coupled to mass spectrometry. *Anal. Biochem* 421, 121–124 (2012). [PubMed: 22093610]
23. Lange JN, Wood KD, Knight J, Assimos DG & Holmes RP Glyoxal formation and its role in endogenous oxalate synthesis. *Adv. Urol* 2012, 819202 (2012). [PubMed: 22567004]
24. Knight J, Wood KD, Lange JN, Assimos DG & Holmes RP Oxalate formation from glyoxal in erythrocytes. *Urology* 10.1016/j.urology.2015.10.014 (2015).
25. Knight J, Assimos DG, Easter L & Holmes RP Metabolism of fructose to oxalate and glycolate. *Horm. Metab. Res* 42, 868–873 (2010). [PubMed: 20842614]
26. Li X et al. Generation of a GLO-2 deficient mouse reveals its effects on liver carbonyl and glutathione levels. *Biochem. Biophys. Rep* 28, 101138 (2021). [PubMed: 34584990]
27. Efe O, Verma A & Waikar SS Urinary oxalate as a potential mediator of kidney disease in diabetes mellitus and obesity. *Curr. Opin. Nephrol. Hypertens* 28, 316–320 (2019). [PubMed: 31045662]

28. Knight J, Assimios DG, Callahan MF & Holmes RP Metabolism of primed, constant infusions of [1,2-¹³C₂] glycine and [1-¹³C₁] phenylalanine to urinary oxalate. *Metabolism* 60, 950–956 (2011). [PubMed: 21036374]
29. Glew RH et al. Nephropathy in dietary hyperoxaluria: a potentially preventable acute or chronic kidney disease. *World J. Nephrol* 3, 122–142 (2014). [PubMed: 25374807]
30. Liu Y et al. Plasma oxalate levels in prevalent hemodialysis patients and potential implications for ascorbic acid supplementation. *Clin. Biochem* 49, 1133–1139 (2016). [PubMed: 27265723]
31. McQuade DJ, Dargan PI & Wood DM Challenges in the diagnosis of ethylene glycol poisoning. *Ann. Clin. Biochem* 51, 167–178 (2013). [PubMed: 24215789]
32. Chai W, Liebman M, Kynast-Gales S & Massey L Oxalate absorption and endogenous oxalate synthesis from ascorbate in calcium oxalate stone formers and non-stone formers. *Am. J. Kidney Dis* 44, 1060–1069 (2004). [PubMed: 15558527]
33. Sikora P et al. [¹³C₂]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. *Kidney Int* 73, 1181–1186 (2008). [PubMed: 18337715]
34. Marengo SR & Romani AMP Oxalate in renal stone disease: the terminal metabolite that just won't go away. *Nat. Clin. Pract. Nephrol* 4, 368–377 (2008). [PubMed: 18523430]
35. Avila-Nava A et al. Oxalate content and antioxidant activity of different ethnic foods. *J. Ren. Nutr* 31, 73–79 (2021). [PubMed: 32709427]
36. Asplin J The management of patients with enteric hyperoxaluria. *Urolithiasis* 10.1007/s00240-015-0846-5 (2015).
37. Whittamore JM & Hatch M Oxalate flux across the intestine: contributions from membrane transporters. *Compr. Physiol* 12, 2835–2875 (2021). [PubMed: 34964122]
38. Elder TD & Wyngaarden JB The biosynthesis and turnover of oxalate in normal and hyperoxaluric subjects. *J. Clin. Invest* 39, 1337–1344 (1960). [PubMed: 13819869]
39. Hautmann R & Osswald H Pharmacokinetic studies of oxalate in man. *Invest. Urol* 16, 395–398 (1979). [PubMed: 429137]
40. Senekjian HO & Weinman EJ Oxalate transport by proximal tubule of the rabbit kidney. *Am. J. Physiol* 243, F271–F275 (1982). [PubMed: 7114257]
41. Costello JF, Smith M, Stolarski C & Sadovnic MJ Extrarenal clearance of oxalate increases with progression of renal failure in the rat. *J. Am. Soc. Nephrol* 3, 1098–1104 (1992). [PubMed: 1482750]
42. Hatch M, Freel RW & Vaziri ND Intestinal excretion of oxalate in chronic renal failure. *J. Am. Soc. Nephrol* 5, 1339–1343 (1994). [PubMed: 7893999]
43. Robijn S, Hoppe B, Vervaeke BA, D'Haese PC & Verhulst A Hyperoxaluria: a gut-kidney axis? *Kidney Int* 80, 1146–1158 (2011). [PubMed: 21866092]
44. Low I, Friedrich T & Burckhardt G Properties of an anion exchanger in rat renal basolateral membrane vesicles. *Am. J. Physiol* 246, F334–F342 (1984). [PubMed: 6703066]
45. Knickelbein RG, Aronson PS & Dobbins JW Oxalate transport by anion exchange across rabbit ileal brush border. *J. Clin. Invest* 77, 170–175 (1986). [PubMed: 3003149]
46. Karniski LP & Aronson PS Anion exchange pathways for Cl⁻ transport in rabbit renal microvillus membranes. *Am. J. Physiol* 253, F513–F521 (1987). [PubMed: 3631282]
47. Kuo SM & Aronson PS Oxalate transport via the sulfate/HCO₃ exchanger in rabbit renal basolateral membrane vesicles. *J. Biol. Chem* 263, 9710–9717 (1988). [PubMed: 3384817]
48. Knickelbein RG & Dobbins JW Sulfate and oxalate exchange for bicarbonate across the basolateral membrane of rabbit ileum. *Am. J. Physiol* 259, G807–G813 (1990). [PubMed: 2240222]
49. Yamakawa K & Kawamura J Oxalate:OH exchange across rat renal cortical brush border membrane. *Kidney Int* 37, 1105–1112 (1990). [PubMed: 2342249]
50. Kuo SM & Aronson PS Pathways for oxalate transport in rabbit renal microvillus membrane vesicles. *J. Biol. Chem* 271, 15491–15497 (1996). [PubMed: 8663096]
51. Jiang Z, Grichtchenko II, Boron WF & Aronson PS Specificity of anion exchange mediated by mouse Slc26a6. *J. Biol. Chem* 277, 33963–33967 (2002). [PubMed: 12119287]

52. Xie Q, Welch R, Mercado A, Romero MF & Mount DB Molecular characterization of the murine Slc26a6 anion exchanger: functional comparison with Slc26a1. *Am. J. Physiol. Ren. Physiol* 283, F826–F838 (2002).
53. Heneghan JF et al. Regulated transport of sulfate and oxalate by SLC26A2/DTDST. *Am. J. Physiol. Cell Physiol* 298, C1363–C1375 (2010). [PubMed: 20219950]
54. Silberg DG, Wang W, Moseley RH & Traber PG The *Down Regulated in Adenoma (dra)* gene encodes an intestine-specific membrane sulfate transport protein. *J. Biol. Chem* 270, 11897–11902 (1995). [PubMed: 7744840]
55. Bai JP et al. Prestin's anion transport and voltage-sensing capabilities are independent. *Biophys. J* 96, 3179–3186 (2009). [PubMed: 19383462]
56. Lohi H et al. Functional characterization of three novel tissue-specific anion exchangers SLC26A7, -A8, and -A9. *J. Biol. Chem* 277, 14246–14254 (2002). [PubMed: 11834742]
57. Stewart AK et al. SLC26 anion exchangers of guinea pig pancreatic duct: molecular cloning and functional characterization. *Am. J. Physiol. Cell Physiol* 301, C289–C303 (2011). [PubMed: 21593449]
58. Jennings ML & Adame MF Characterization of oxalate transport by the human erythrocyte band 3 protein. *J. Gen. Physiol* 107, 145–159 (1996). [PubMed: 8741736]
59. Reimold FR et al. Substitution of transmembrane domain Cys residues alters pH(o)-sensitive anion transport by AE2/SLC4A2 anion exchanger. *Pflug. Arch* 465, 839–851 (2013).
60. Knauf F et al. Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. *J. Am. Soc. Nephrol* 22, 2247–2255 (2011). [PubMed: 22021714]
61. Freel RW, Whittamore JM & Hatch M Transcellular oxalate and Cl⁻ absorption in mouse intestine is mediated by the DRA anion exchanger Slc26a3, and DRA deletion decreases urinary oxalate. *Am. J. Physiol. Gastrointest. Liver Physiol* 305, G520–G527 (2013). [PubMed: 23886857]
62. Cil O, Chu T, Lee S, Haggie PM & Verkman AS Small-molecule inhibitor of intestinal anion exchanger SLC26A3 for treatment of hyperoxaluria and nephrolithiasis. *JCI Insight* 10.1172/jci.insight.153359 (2022).
63. Chernova MN et al. Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in *Xenopus* oocytes. *J. Physiol* 549, 3–19 (2003). [PubMed: 12651923]
64. Wasiluk T et al. Simultaneous expression of ClopHensor and SLC26A3 reveals the nature of endogenous oxalate transport in CHO cells. *Biol. Open* 10.1242/bio.041665 (2019).
65. Chernova MN et al. Functional comparison of mouse slc26a6 anion exchanger with human SLC26A6 polypeptide variants: differences in anion selectivity, regulation, and electrogenicity. *J. Biol. Chem* 280, 8564–8580 (2005). [PubMed: 15548529]
66. Freel RW, Hatch M, Green M & Soleimani M Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. *Am. J. Physiol. Gastrointest. Liver Physiol* 290, G719–G728 (2006). [PubMed: 16373425]
67. Jiang Z et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. *Nat. Genet* 38, 474–478 (2006). [PubMed: 16532010]
68. Liu Y et al. Short-Chain fatty acids reduced renal calcium oxalate stones by regulating the expression of intestinal oxalate transporter SLC26A6. *mSystems* 6, e0104521 (2021). [PubMed: 34783577]
69. Whittamore JM & Hatch M The anion exchanger PAT-1 (Slc26a6) does not participate in oxalate or chloride transport by mouse large intestine. *Pflug. Arch* 473, 95–106 (2021).
70. Capolongo G, Abul-Ezz S, Moe OW & Sakhae K Subclinical celiac disease and crystal-induced kidney disease following kidney transplant. *Am. J. Kidney Dis* 60, 662–667 (2012). [PubMed: 22739230]
71. Cornière N et al. Dominant negative mutation in oxalate transporter *SLC26A6* associated with enteric hyperoxaluria and nephrolithiasis. *J. Med. Genet* 10.1136/jmedgenet-2021-108256 (2022).
72. Mukaibo T et al. The apical anion exchanger Slc26a6 promotes oxalate secretion by murine submandibular gland acinar cells. *J. Biol. Chem* 293, 6259–6268 (2018). [PubMed: 29530983]

73. Bissig M, Hagenbuch B, Stieger B, Koller T & Meier PJ Functional expression cloning of the canalicular sulfate transport system of rat hepatocytes. *J. Biol. Chem* 269, 3017–3021 (1994). [PubMed: 8300633]
74. Karniski LP et al. Immunolocalization of sat-1 sulfate/oxalate/bicarbonate anion exchanger in the rat kidney. *Am. J. Physiol* 275, F79–F87 (1998). [PubMed: 9689008]
75. Lee A, Beck L & Markovich D The mouse sulfate anion transporter gene *Sat1* (Slc26a1): cloning, tissue distribution, gene structure, functional characterization, and transcriptional regulation thyroid hormone. *DNA Cell Biol* 22, 19–31 (2003). [PubMed: 12590734]
76. Quondamatteo F et al. Localization of the sulfate/anion exchanger in the rat liver. *Am. J. Physiol. Gastrointest. Liver Physiol* 290, G1075–G1081 (2006). [PubMed: 16357056]
77. Krick W, Schnedler N, Burckhardt G & Burckhardt BC Ability of sat-1 to transport sulfate, bicarbonate, or oxalate under physiological conditions. *Am. J. Physiol. Ren. Physiol* 297, F145–F154 (2009).
78. Dawson PA et al. Urolithiasis and hepatotoxicity are linked to the anion transporter Sat1 in mice. *J. Clin. Invest* 120, 706–712 (2010). [PubMed: 20160351]
79. Ko N, Knauf F, Jiang Z, Markovich D & Aronson PS Sat1 is dispensable for active oxalate secretion in mouse duodenum. *Am. J. Physiol. Cell Physiol* 303, C52–C57 (2012). [PubMed: 22517357]
80. Whittamore JM, Stephens CE & Hatch M Absence of the sulfate transporter SAT-1 has no impact on oxalate handling by mouse intestine and does not cause hyperoxaluria or hyperoxalemia. *Am. J. Physiol. Gastrointest. Liver Physiol* 316, G82–G94 (2019). [PubMed: 30383413]
81. Gee HY et al. Mutations in *SLC26A1* cause nephrolithiasis. *Am. J. Hum. Genet* 98, 1228–1234 (2016). [PubMed: 27210743]
82. Lohi H et al. Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a candidate gene for pancreatic anion exchanger. *Genomics* 70, 102–112 (2000). [PubMed: 11087667]
83. Waldegger S et al. Cloning and characterization of *SLC26A6*, a novel member of the solute carrier 26 gene family. *Genomics* 72, 43–50 (2001). [PubMed: 11247665]
84. Knauf F et al. Identification of a chloride-formate exchanger expressed on the brush border membrane of renal proximal tubule cells. *Proc. Natl Acad. Sci. USA* 98, 9425–9430 (2001). [PubMed: 11459928]
85. Wang Z, Petrovic S, Mann E & Soleimani M Identification of an apical $\text{Cl}^-/\text{HCO}_3^-$ exchanger in the small intestine. *Am. J. Physiol. Gastrointest. Liver Physiol* 282, G573–G579 (2002). [PubMed: 11842009]
86. Sugimoto T et al. Fate of circulating oxalate in rats. *Eur. Urol* 23, 485–489 (1993). [PubMed: 8335055]
87. Weinman EJ, Frankfurt SJ, Ince A & Sansom S Renal tubular transport of organic acids. Studies with oxalate and para-aminohippurate in the rat. *J. Clin. Invest* 61, 801–806 (1978). [PubMed: 641156]
88. Knauf F, Velazquez H, Pfann V, Jiang Z & Aronson PS Characterization of renal NaCl and oxalate transport in *Slc26a6*^{-/-} mice. *Am. J. Physiol. Ren. Physiol* 316, F128–F133 (2019).
89. Holmes RP, Ambrosius WT & Assimos DG Dietary oxalate loads and renal oxalate handling. *J. Urol* 174, 943–947 (2005). [PubMed: 16094002]
90. Worcester EM et al. A test of the hypothesis that oxalate secretion produces proximal tubule crystallization in primary hyperoxaluria type I. *Am. J. Physiol. Ren. Physiol* 305, F1574–F1584 (2013).
91. Chandhoke PS & Fan J Transport of oxalate across the rabbit papillary surface epithelium. *J. Urol* 164, 1724–1728 (2000). [PubMed: 11025759]
92. Ohana E, Shehynikov N, Moe OW & Muallem S SLC26A6 and NaDC-1 transporters interact to regulate oxalate and citrate homeostasis. *J. Am. Soc. Nephrol* 24, 1617–1626 (2013). [PubMed: 23833257]
93. Lloyd-Price J et al. Strains, functions and dynamics in the expanded Human Microbiome Project. *Nature* 550, 61–66 (2017). [PubMed: 28953883]

94. The Integrative HMP (iHMP) Research Network Consortium. The Integrative Human Microbiome Project. *Nature* 569, 641–648 (2019). [PubMed: 31142853]
95. Abratt VR & Reid SJ Oxalate-degrading bacteria of the human gut as probiotics in the management of kidney stone disease. *Adv. Appl. Microbiol* 72, 63–87 (2010). [PubMed: 20602988]
96. Daniel SL et al. Forty years of *Oxalobacter formigenes*, a gutsy oxalate-degrading specialist. *Appl. Environ. Microbiol* 87, e0054421 (2021). [PubMed: 34190610]
97. Arvans D et al. *Oxalobacter formigenes*-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. *J. Am. Soc. Nephrol* 28, 876–887 (2017). [PubMed: 27738124]
98. Hatch M & Freel RW A human strain of *Oxalobacter* (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion. *Urolithiasis* 41, 379–384 (2013). [PubMed: 23959075]
99. Tasian GE et al. Oral antibiotic exposure and kidney stone disease. *J. Am. Soc. Nephrol* 29, 1731–1740 (2018). [PubMed: 29748329]
100. Ferraro PM, Curhan GC, Gambaro G & Taylor EN Antibiotic use and risk of incident kidney stones in female nurses. *Am. J. Kidney Dis* 74, 736–741 (2019). [PubMed: 31543288]
101. Nazzal L & Blaser MJ Does the receipt of antibiotics for common infectious diseases predispose to kidney stones? A cautionary note for all health care practitioners. *J. Am. Soc. Nephrol* 29, 1590–1592 (2018). [PubMed: 29748328]
102. Miller AW & Dearing D The metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut. *Pathogens* 2, 636–652 (2013). [PubMed: 25437337]
103. Ticinesi A et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. *Gut* 67, 2097–2106 (2018). [PubMed: 29705728]
104. Suryavanshi MV et al. Hyperoxaluria leads to dysbiosis and drives selective enrichment of oxalate metabolizing bacterial species in recurrent kidney stone endures. *Sci. Rep* 6, 34712 (2016). [PubMed: 27708409]
105. Denburg MR et al. Perturbations of the gut microbiome and metabolome in children with calcium oxalate kidney stone disease. *J. Am. Soc. Nephrol* 31, 1358–1369 (2020). [PubMed: 32381601]
106. Kaufman DW et al. *Oxalobacter formigenes* may reduce the risk of calcium oxalate kidney stones. *J. Am. Soc. Nephrol* 19, 1197–1203 (2008). [PubMed: 18322162]
107. Ticinesi A, Nouvenne A & Meschi T Gut microbiome and kidney stone disease: not just an *Oxalobacter* story. *Kidney Int* 96, 25–27 (2019). [PubMed: 31229040]
108. Miller AW, Choy D, Penniston KL & Lange D Inhibition of urinary stone disease by a multi-species bacterial network ensures healthy oxalate homeostasis. *Kidney Int* 96, 180–188 (2019). [PubMed: 31130222]
109. Dill H, Martin-Higuera C & Hoppe B Diet-related urine collections: assistance in categorization of hyperoxaluria. *Urolithiasis* 10.1007/s00240-021-01290-2 (2021).
110. Shee K & Stoller ML Perspectives in primary hyperoxaluria — historical, current and future clinical interventions. *Nat. Rev. Urol* 10.1038/s41585-021-00543-4 (2021).
111. Martin-Higuera C et al. A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3. *Kidney Int* 100, 621–635 (2021). [PubMed: 33865885]
112. Garrelfs SF et al. Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up. *Kidney Int* 96, 1389–1399 (2019). [PubMed: 31685312]
113. Hopp K et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. *J. Am. Soc. Nephrol* 26, 2559–2570 (2015). [PubMed: 25644115]
114. Mandrile G et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. *Kidney Int* 86, 1197–1204 (2014). [PubMed: 24988064]
115. Zhao Y et al. Extended genetic analysis of exome sequencing for primary hyperoxaluria in pediatric urolithiasis patients with hyperoxaluria. *Gene* 10.1016/j.gene.2021.146155 (2022).

116. Tu X et al. Human MiR-4660 regulates the expression of alanine-glyoxylate aminotransferase and may be a biomarker for idiopathic oxalosis. *Clin. Exp. Nephrol* 23, 890–897 (2019). [PubMed: 30852714]
117. Belostotsky R et al. Translation inhibition corrects aberrant localization of mutant alanine-glyoxylate aminotransferase: possible therapeutic approach for hyperoxaluria. *J. Mol. Med* 96, 621–630 (2018). [PubMed: 29777253]
118. Lorenz EC et al. Recovery from dialysis in patients with primary hyperoxaluria type 1 treated with pyridoxine: a report of 3 cases. *Am. J. Kidney Dis* 77, 816–819 (2021). [PubMed: 32891627]
119. Dindo M, Oppici E, Dell’Orco D, Montone R & Cellini B Correlation between the molecular effects of mutations at the dimer interface of alanine-glyoxylate aminotransferase leading to primary hyperoxaluria type I and the cellular response to vitamin B(6). *J. Inherit. Metab. Dis* 41, 263–275 (2018). [PubMed: 29110180]
120. Monico CG, Rossetti S, Olson JB & Milliner DS Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. *Kidney Int* 67, 1704–1709 (2005). [PubMed: 15840016]
121. Dindo M et al. Dimerization drives proper folding of human alanine:glyoxylate aminotransferase but is dispensable for peroxisomal targeting. *J. Pers. Med* 10.3390/jpm11040273 (2021).
122. Reddy S et al. Clinical outcomes and histological patterns in oxalate nephropathy due to enteric and nonenteric risk factors. *Am. J. Nephrol* 10.1159/000520286 (2021).
123. Joshi S, Wang W & Khan SR Transcriptional study of hyperoxaluria and calcium oxalate nephrolithiasis in male rats: Inflammatory changes are mainly associated with crystal deposition. *PLoS ONE* 12, e0185009 (2017). [PubMed: 29091707]
124. Ogawa Y et al. Calcium oxalate saturation in dialysis patients with and without primary hyperoxaluria. *Urol. Res* 34, 12–16 (2006). [PubMed: 16432691]
125. Worcester EM, Nakagawa Y, Bushinsky DA & Coe FL Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure. *J. Clin. Invest* 77, 1888–1896 (1986). [PubMed: 3711339]
126. Hueppelshaeuser R et al. Enteric hyperoxaluria, recurrent urolithiasis, and systemic oxalosis in patients with Crohn’s disease. *Pediatr. Nephrol* 27, 1103–1109 (2012). [PubMed: 22366809]
127. Shah RJ, Vaughan LE, Enders FT, Milliner DS & Lieske JC Plasma oxalate as a predictor of kidney function decline in a primary hyperoxaluria cohort. *Int. J. Mol. Sci* 21, 3608 (2020). [PubMed: 32443777]
128. Mulay SR et al. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. *Am. J. Physiol. Ren. Physiol* 10.1152/ajprenal.00488.2015 (2016).
129. Tubben A et al. Urinary oxalate excretion and long-term outcomes in kidney transplant recipients. *J. Clin. Med* 10.3390/jcm8122104 (2019).
130. Pinheiro HS, Camara NO, Osaki KS, De Moura LA & Pacheco-Silva A Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. *Am. J. Transpl* 5, 323–329 (2005).
131. Palsson R et al. The association of calcium oxalate deposition in kidney allografts with graft and patient survival. *Nephrol. Dial. Transpl* 35, 888–894 (2020).
132. Krogstad V et al. High plasma oxalate levels early after kidney transplantation are associated with impaired long-term outcomes. *Transpl. Int* 35, 10240 (2022). [PubMed: 35368646]
133. Rule AD, Krambeck AE & Lieske JC Chronic kidney disease in kidney stone formers. *Clin. J. Am. Soc. Nephrol* 6, 2069–2075 (2011).
134. Amin R et al. Reduced active transcellular intestinal oxalate secretion contributes to the pathogenesis of obesity-associated hyperoxaluria. *Kidney Int* 93, 1098–1107 (2018). [PubMed: 29395336]
135. Gianmoena K et al. Epigenomic and transcriptional profiling identifies impaired glyoxylate detoxification in NAFLD as a risk factor for hyperoxaluria. *Cell Rep* 36, 109526 (2021). [PubMed: 34433051]



136. Evan AP et al. Renal histopathology and crystal deposits in patients with small bowel resection and calcium oxalate stone disease. *Kidney Int* 78, 310–317 (2010). [PubMed: 20428098]
137. Convento MB et al. Calcium oxalate crystals and oxalate induce an epithelial-to-mesenchymal transition in the proximal tubular epithelial cells: contribution to oxalate kidney injury. *Sci. Rep* 7, 45740 (2017). [PubMed: 28387228]
138. Convento M, Pessoa E, Aragão A, Schor N & Borges F Oxalate induces type II epithelial to mesenchymal transition (EMT) in inner medullary collecting duct cells (IMCD) in vitro and stimulate the expression of osteogenic and fibrotic markers in kidney medulla in vivo. *Oncotarget* 10, 1102–1118 (2019). [PubMed: 30800221]
139. Liu Y et al. Role of ROS-induced NLRP3 inflammasome activation in the formation of calcium oxalate nephrolithiasis. *Front. Immunol* 13, 818625 (2022). [PubMed: 35154136]
140. Kohri K et al. Biomolecular mechanism of urinary stone formation involving osteopontin. *Urol. Res* 40, 623–637 (2012). [PubMed: 23124115]
141. Khan SR, Canales BK & Dominguez-Gutierrez PR Randall's plaque and calcium oxalate stone formation: role for immunity and inflammation. *Nat. Rev. Nephrol* 17, 417–433 (2021). [PubMed: 33514941]
142. Patel M et al. Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. *Redox Biol* 15, 207–215 (2018). [PubMed: 29272854]
143. Kumar P, Saini K, Saini V & Mitchell T Oxalate alters cellular bioenergetics, redox homeostasis, antibacterial response, and immune response in macrophages. *Front. Immunol* 12, 694865 (2021). [PubMed: 34745086]
144. Recht PA et al. Oxalic acid alters intracellular calcium in endothelial cells. *Atherosclerosis* 173, 321–328 (2004). [PubMed: 15064109]
145. Bao Y, Tu X & Wei Q Water for preventing urinary stones. *Cochrane Database Syst. Rev* 2, CD004292 (2020).
146. Kumar R et al. Fat malabsorption and increased intestinal oxalate absorption are common after roux-en-Y gastric bypass surgery. *Surgery* 149, 654–661 (2011). [PubMed: 21295813]
147. Cheungpasitporn W, Erickson SB, Rule AD, Enders F & Lieske JC Short-term tolvaptan increases water intake and effectively decreases urinary calcium oxalate, calcium phosphate and uric acid supersaturations. *J. Urol* 195, 1476–1481 (2016). [PubMed: 26598423]
148. Reilly RF, Peixoto AJ & Desir GV The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. *Clin. J. Am. Soc. Nephrol* 5, 1893 (2010). [PubMed: 20798254]
149. Phillips R et al. Citrate salts for preventing and treating calcium containing kidney stones in adults. *Cochrane Database Syst. Rev* 10, CD010057 (2015).
150. Chung J et al. Molecular modifiers reveal a mechanism of pathological crystal growth inhibition. *Nature* 536, 446–450 (2016). [PubMed: 27501150]
151. Ruggenenti P et al. Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: a pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial. *EClinicalMedicine* 43, 101227 (2022). [PubMed: 34977512]
152. Espino-Grosso P, Monsour C & Canales BK The effect of calcium and vitamin B6 Supplementation on oxalate excretion in a rodent gastric bypass model of enteric hyperoxaluria. *Urology* 124, 310.e9–310.e14 (2019).
153. Nazzari L, Puri S & Goldfarb DS Enteric hyperoxaluria: an important cause of end-stage kidney disease. *Nephrol. Dial. Transplant* 31, 375–382 (2015). [PubMed: 25701816]
154. Emmett M et al. Conjugated bile acid replacement therapy reduces urinary oxalate excretion in short bowel syndrome. *Am. J. Kidney Dis* 41, 230–237 (2003). [PubMed: 12500242]
155. Oka Y, Miyazaki M, Takatsu S & Matsuda H Calcium-based phosphate binders and plasma oxalate concentration in dialysis patients. *J. Am. Soc. Nephrol* 10.1681/ASN.2022030248 (2022).
156. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int. Suppl* 7, 1–59 (2017).

157. US National Library of Medicine. [ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03346369](https://clinicaltrials.gov/ct2/show/NCT03346369) (2017).
158. Lieske JC, Regnier C & Dillon JJ Use of sevelamer hydrochloride as an oxalate binder. *J. Urol* 179, 1407–1410 (2008). [PubMed: 18289565]
159. Vekeman J et al. In search of an efficient complexing agent for oxalates and phosphates: a quantum chemical study. *Nanomaterials* 10.3390/nano11071763 (2021).
160. Canales BK & Hatch M *Oxalobacter formigenes* colonization normalizes oxalate excretion in a gastric bypass model of hyperoxaluria. *Surg. Obes. Relat. Dis* 13, 1152–1157 (2017). [PubMed: 28552742]
161. Milliner D, Hoppe B & Groothoff J A randomised phase II/III study to evaluate the efficacy and safety of orally administered *Oxalobacter formigenes* to treat primary hyperoxaluria. *Urolithiasis* 46, 313–323 (2018). [PubMed: 28718073]
162. Hoppe B et al. Effects of *Oxalobacter formigenes* in subjects with primary hyperoxaluria Type 1 and end-stage renal disease: a phase II study. *Nephrol. Dial. Transplant* 36, 1464–1473 (2020).
163. Klimesova K, Whittamore JM & Hatch M *Bifidobacterium animalis* subsp. *lactis* decreases urinary oxalate excretion in a mouse model of primary hyperoxaluria. *Urolithiasis* 43, 107–117 (2015). [PubMed: 25269440]
164. Lieske JC, Goldfarb DS, De Simone C & Regnier C Use of a probiotic to decrease enteric hyperoxaluria. *Kidney Int* 68, 1244–1249 (2005). [PubMed: 16105057]
165. US National Library of Medicine. [ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04909723](https://clinicaltrials.gov/ct2/show/NCT04909723) (2021).
166. Mehra Y & Viswanathan P High-quality whole-genome sequence analysis of *Lactobacillus paragasseri* UBLG-36 reveals oxalate-degrading potential of the strain. *PLoS ONE* 16, e0260116 (2021). [PubMed: 34797858]
167. Lubkowicz D et al. An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria. *Mol. Syst. Biol* 18, e10539 (2022). [PubMed: 35253995]
168. Miller AW, Dale C & Dearing MD The induction of oxalate metabolism in vivo is more effective with functional microbial communities than with functional microbial species. *mSystems* 10.1128/mSystems.00088-17 (2017).
169. Miller AW, Oakeson KF, Dale C & Dearing MD Microbial community transplant results in increased and long-term oxalate degradation. *Microb. Ecol* 72, 470–478 (2016). [PubMed: 27312892]
170. Stern JM et al. Fecal transplant modifies urine chemistry risk factors for urinary stone disease. *Physiol. Rep* 7, e14012 (2019). [PubMed: 30789675]
171. Quintero E et al. A prospective, double-blind, randomized, placebo-controlled, crossover study using an orally administered oxalate decarboxylase (OxDC). *Kidney360* 1, 1284–1290 (2020). [PubMed: 35372879]
172. US National Library of Medicine. [ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT01127087](https://clinicaltrials.gov/ct2/show/study/NCT01127087) (2010).
173. Lingeman JE et al. ALLN-177, oral enzyme therapy for hyperoxaluria. *Int. Urol. Nephrol* 51, 601–608 (2019). [PubMed: 30783888]
174. Pfau A et al. Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. *Nephrol. Dial. Transpl* 36, 945–948 (2021).
175. Lieske John C et al. Randomized placebo-controlled trial of reloxaliase in enteric hyperoxaluria. *NEJM Evid* 1, EVIDoa2100053 (2022).
176. Dejban P & Lieske JC New therapeutics for primary hyperoxaluria type 1. *Curr. Opin. Nephrol. Hypertens* 31, 344–350 (2022). [PubMed: 35266883]
177. Aagaard L & Rossi JJ RNAi therapeutics: principles, prospects and challenges. *Adv. Drug Deliv. Rev* 59, 75–86 (2007). [PubMed: 17449137]
178. Traber GM & Yu A-M RNAi based therapeutics and novel RNA bioengineering technologies. *J. Pharmacol. Exp. Ther* 10.1124/jpet.122.001234 (2022).

179. Garrelfs SF et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. *N. Engl. J. Med* 384, 1216–1226 (2021). [PubMed: 33789010]
180. Sas DJ et al. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: a new RNAi therapeutic in infants and young children. *Genet. Med* 10.1016/j.gim.2021.10.024 (2021).
181. Leth PM & Gregersen M Ethylene glycol poisoning. *Forensic Sci. Int* 155, 179–184 (2005). [PubMed: 16226155]
182. Méaux MN et al. The effect of lumasiran therapy for primary hyperoxaluria type 1 in small infants. *Pediatr. Nephrol* 10.1007/s00467-021-05393-1 (2022).
183. Joher N et al. Early post-transplant recurrence of oxalate nephropathy in a patient with primary hyperoxaluria type 1, despite pretransplant lumasiran therapy. *Kidney Int* 101, 185–186 (2022). [PubMed: 34991805]
184. Shee K et al. Nedosiran dramatically reduces serum oxalate in dialysis-dependent primary hyperoxaluria 1: a compassionate use case report. *Urology* 156, e147–e149 (2021). [PubMed: 33774044]
185. Hoppe B et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. *Kidney Int* 10.1016/j.kint.2021.08.015 (2021).
186. Zabaleta N et al. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I. *Nat. Commun* 9, 5454 (2018). [PubMed: 30575740]
187. Zheng R et al. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1. *Clin. Transl Med* 10, e261 (2020). [PubMed: 33377632]
188. Martinez-Turrillas R et al. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria. *Mol. Ther. Methods Clin. Dev* 25, 137–146 (2022). [PubMed: 35402636]
189. Mulay SR Multifactorial functions of the inflammasome component NLRP3 in pathogenesis of chronic kidney diseases. *Kidney Int* 96, 58–66 (2019). [PubMed: 30922667]
190. Song Z et al. Long noncoding RNA LINC00339 promotes renal tubular epithelial pyroptosis by regulating the miR-22–3p/NLRP3 axis in calcium oxalate-induced kidney stone. *J. Cell. Biochem* 120, 10452–10462 (2019). [PubMed: 30614043]
191. Lu C-L, Teng T-Y, Liao M-T & Ma M-C TRPV1 hyperfunction contributes to renal inflammation in oxalate nephropathy. *Int. J. Mol. Sci* 22, 6204 (2021). [PubMed: 34201387]
192. Ludwig-Portugall I et al. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. *Kidney Int* 90, 525–539 (2016). [PubMed: 27262364]
193. Holmes RP & Assimos DG Glyoxylate synthesis and its modulation and influence on oxalate synthesis. *J. Urol* 160, 1617–1624 (1998). [PubMed: 9783918]
194. Clark B, Baqdues MW & Kunkel GM Diet-induced oxalate nephropathy. *BMJ Case Rep* 12, e231284 (2019).
195. US National Library of Medicine. [ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/study/NCT04860492](https://clinicaltrials.gov/ct2/show/study/NCT04860492) (2021).
196. Lieske JC et al. Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. *Kidney Int* 78, 1178–1185 (2010). [PubMed: 20736987]
197. Pape L, Ahlenstiel-Grunow T, Birtel J, Krohne TU & Hoppe B *Oxalobacter formigenes* treatment combined with intensive dialysis lowers plasma oxalate and halts disease progression in a patient with severe infantile oxalosis. *Pediatr. Nephrol* 10.1007/s00467-019-04463-9 (2020).
198. Lorenz EC et al. Sustained pyridoxine response in primary hyperoxaluria type 1 recipients of kidney alone transplant. *Am. J. Transplant* 14, 1433–1438 (2014). [PubMed: 24797341]
199. Hoyer-Kuhn H et al. Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. *Clin. J. Am. Soc. Nephrol* 9, 468–477 (2014). [PubMed: 24385516]

Key points

- Oxalate homeostasis is maintained through a combination of endogenous biosynthesis, exogenous supply, and renal and faecal excretion. Disruptions to these mechanisms caused by genetic mutations (primary hyperoxaluria) or increased oxalate absorption (secondary hyperoxaluria) result in oxalate nephropathy.
- Solute carrier family 26 member 6 anion transporter has an important role in the maintenance of oxalate homeostasis by facilitating transcellular oxalate secretion in the intestine (in contrast to paracellular absorption).
- Among several oxalate-degrading bacteria in the human gut microbiota, *Oxalobacter formigenes* represents a major reservoir of oxalate-metabolizing genes.
- Oxalate inhibits kidney epithelial cell proliferation, promotes fibrotic transformation, calcification and atherosclerosis, and induces cell death. These pathological pathways are probably mediated, at least in part, through NLRP3 inflammasome stimulation and mitochondrial disruption.
- Urinary oxalate excretion is independently associated with the progression of chronic kidney disease and kidney failure. Elevated blood oxalate is also associated with increased risk of cardiovascular events, in particular sudden cardiac death.
- Oxalate-balancing treatment options include *O. formigenes* analogues and oxalate decarboxylase supplements, small interfering RNA therapeutics that target oxalate-producing hepatic enzymes, and experimental CRISPR–Cas9 approaches and anti-inflammatory strategies.

a Physiological oxalate homeostasis**b Disturbed oxalate homeostasis and the consequences of hyperoxalaemia**
Primary hyperoxaluria**Fig. 1 | Oxalate homeostasis.**

a, Physiological oxalate homeostasis. Oxalate homeostasis is maintained by a delicate interplay of supply (that is, hepatic production, gastrointestinal (GI) absorption of dietary oxalate and tubular reabsorption of circulating oxalate) and excretion (GI secretion and faecal oxalate, glomerular filtration, tubular secretion and urinary oxalate). Physiological plasma oxalate concentrations of 1–5 μM have no known negative effects on the cardiovascular system. **b**, Disturbed oxalate homeostasis and the consequences of hyperoxalaemia. Oxalate homeostasis might be disturbed by alterations in numerous pathways. Plasma oxalate concentrations can increase owing to decreased urinary excretion

in chronic kidney disease, increased hepatic production in primary hyperoxaluria or increased GI absorption in enteric hyperoxaluria. When kidney function is still sufficiently high to enable compensatory oxalate excretion in the kidney, hyperoxaluria can result in nephrocalcinosis, tubular toxicity and obstruction. Loss of kidney excretory function can lead to supersaturation of plasma with oxalate, which can have severe adverse effects on the cardiovascular system. High plasma oxalate is associated with sudden cardiac death, coronary artery disease, congestive heart failure and vascular calcification. Oxalate can also deposit in other tissues such as bone, thyroid, spleen and lungs.




Fig. 2 | Model of endogenous oxalate synthesis pathways.

Glyoxylate links several metabolic pathways and is thought to be the principal precursor molecule of endogenous oxalate in healthy humans. Glyoxylate sources include hydroxyproline¹⁹, which is derived from collagen metabolism and is metabolized to 4-hydroxy-2-oxoglutarate (HOG) and its reduced form 2,4-dihydroxyglutarate (DHG) via three steps in the mitochondrion; HOG can be converted to glyoxylate by 4-hydroxy-2-oxoglutarate aldolase type 1 (HOGA1). Deficiency of HOGA1 results in primary hyperoxaluria type 3 (PH3) but the exact mechanism by which oxalate accumulates in this condition is not clear⁴. The accumulation of HOG might inhibit glyoxylate reductase/hydroxypyruvate reductase (GRHPR), which is ubiquitous in cytosol and mitochondria, and converts glyoxylate to glycolate; GRHPR deficiency causes PH2. The amino acid glycine is also converted to glyoxylate by d-amino acid oxidase (DAO) in the peroxisome. Deficiency of liver-specific, peroxisomal alanine–glyoxylate aminotransferase (AGT), which converts glyoxylate to glycine, results in PH1. In addition to glyoxylate, glycolate²² can be derived from sources such as glyoxal, which is a peroxidation product converted to glycolate by the glyoxalase system. Several other processes contribute to glycolate formation, including DNA repair (2-phosphoglycolate is converted to glycolate by phosphoglycolate phosphatase) and fructose or ethylene glycol metabolism (glycolaldehyde is converted to glycolate by aldehyde dehydrogenase). Glycolate is then converted to glyoxylate by liver-specific, peroxisomal glycolate oxidase (GO; also known as HAOX1). Glyoxylate is converted to oxalate by liver-specific lactate dehydrogenase A (LDHA).

Oxalate transport in the small intestine




Fig. 3 | Oxalate transport in the small intestine. Most oxalate absorption in the small intestine occurs passively through the paracellular pathway. Transcellular oxalate secretion is mediated by apical membrane Cl⁻-oxalate exchange through the transporter solute carrier family 26 member 6 (SLC26A6). The transporter on the basolateral membrane that operates in combination with apical SLC26A6 to mediate transcellular oxalate secretion in the small intestine has not yet been identified.

Microbial modulation of oxalate homeostasis




Fig. 4 |. Microbial modulation of oxalate homeostasis.

Dietary oxalate is degraded by several species of the intestinal microbiota, which can reduce the amount of oxalate available for intestinal absorption. Several bacterial species can degrade oxalate, including *Oxalobacter formigenes*, *Escherichia coli*, *Bifidobacterium* spp. and *Lactobacillus* spp. *O. formigenes* also releases a secretagogue that induces oxalate secretion into the gut. Several microbiome-based therapies are being developed to enhance oxalate degradation and reduce oxalate absorption in the gastrointestinal tract. These therapies include supplementation with oxalate-degrading bacterial communities, use of the enzyme oxalate decarboxylase, which metabolizes oxalate, and use of the *E. coli* Nissle strain, which has been genetically modified to encode the oxalate degradation pathway genes that encode oxalyl-CoA decarboxylase (*oxdC*) and formyl-CoA:oxalate CoA-transferase (*frc*).

Table 1 |

Major sources of endogenous and exogenous oxalate

Source	Pathway	(Patho)physiological roles
Endogenous sources		
Glycolate	Derived from glyoxal and glyoxylate metabolism, DNA repair, fructose, ethylene glycol ^{22,25}	Contributes to 1.3% of oxalogenesis in healthy individuals and 47.3% in PH1; diagnostic marker in PH1 (ref. ¹¹⁰); metabolite involved in ethylene glycol poisoning
Hydroxyproline	Derived from collagen catabolism ¹⁹	Contributes to 15% of urinary oxalate in healthy individuals, and to 18%, 47% and 33% in PH1, PH2 and PH3, respectively ¹⁹
Glycine	Amino acid ²⁸	Contributes to <5% of urinary oxalate in healthy individuals ²⁸
Glyoxal	Advanced glycation end-product; also derived from glucose metabolism and lipid peroxidation ^{23,24}	Potential link to diabetes ^{23,27}
Glyoxylate	Metabolic product generated from 4-hydroxy-2-oxoglutarate, glycolate, glyoxal or glycine ^{19,25}	Liver intermediary metabolism linking several metabolic pathways ¹⁹³
Exogenous sources (via excessive ingestion)		
Vegetables	Spinach, rhubarb, beets, sweet potato, Chaga mushroom	Oxalate nephropathy
Beverages	Cocoa powder, coffee, some types of tea	Can cause ice (black) tea-induced oxalate nephropathy
Proteins and carbohydrates	Soy, legumes, rice bran, wheatgerm, commel, wholegrain flour	Diet-induced oxalate nephropathy in patients with diabetes ¹⁹⁴
Fruits	Starfruit, guava, watermelon, raspberries	Starfruit-induced oxalate nephropathy
Seeds and nuts	Chia seeds, peanuts, sesame seeds, almonds, amaranth, hazelnuts, pistachios	Oxalate nephropathy induced by peanut, chia and almond consumption
Supplements	Vitamin C (ascorbic acid)	Vitamin C-induced hyperoxaluria, nephrolithiasis and oxalate nephropathy

PH1, primary hyperoxaluria 1.

Table 2 |

Primary hyperoxaluria types, diagnostics and manifestations

Type (% of PH cases)	Affected enzyme	Diagnostics	Manifestations
PH1 (refs. ^{110,113}) (~80%)	AGT; >200 <i>AGXT</i> mutations described	Clinical presentation, high glycolate (non-specific) and high oxalate in urine and plasma, genetic analysis	Reported age of onset 0.1–53 years ¹¹³ ; median urinary oxalate excretion: 1.8 mmol/1.73 m ² /day ¹¹³ (vitamin B6-responsive PH1: 0.94 mmol/1.73 m ² /day; vitamin B6-non-responsive PH1: 1.37 mmol/1.73 m ² /day ¹¹¹); progression to CKD (>73% of patients) and kidney failure (>50% of patients) ¹¹⁴
PH2 (refs. ^{111–113}) (7.9–10%)	GRHPR; at least 39 <i>GRHPR</i> mutations described	Clinical presentation, high L-glycerate (non-specific) in urine and high oxalate in plasma and urine, genetic analysis	Reported age of onset 0.6–42 years ¹¹³ ; median urinary oxalate excretion: 1.4–1.7 mmol/1.73 m ² /day ^{111,113} ; progression to CKD (50% of patients) and kidney failure (25% of patients) ^{111,112}
PH3 (refs. ^{111,113}) (8.4–17%)	HOGAI; at least 37 <i>HOGAI</i> mutations described	Clinical presentation, high 4-hydroxy-2-oxoglutarate or 2,4-dihydroxyglutarate in urine and high oxalate in plasma and urine, genetic analysis	Reported age of onset 0.3–48 years ^{111,113} ; median urinary oxalate excretion: 1.1–1.16 mmol/1.73 m ² /day ^{111,113} ; progression to CKD (~20% of patients) and kidney failure (one case reported) ^{111,113}

AGT, alanine-glyoxylate aminotransferase; CKD, chronic kidney disease; GRHPR, glyoxylate reductase/hydroxypyruvate reductase; HOGAI, 4-hydroxy-2-oxoglutarate aldolase type 1; PH1, primary hyperoxaluria type 1.

Table 3 |

Promising novel therapeutic options targeting oxalate dysregulation

Strategy	Primary indication	Clinical evidence	Experimental evidence only
Prevention of urinary calcium oxalate crystallization	Nephrolithiasis	Hyperhydrat ^{110,145,146} , tolvaptan ¹⁴⁷ , thiazides ¹⁴⁸ , (hydroxy)citra ^{149,150} , lemon juice ¹⁵¹ , ^a , active <i>Agropyron repens</i> extract ¹⁹⁵	NA
Prevention of intestinal hyperabsorption	All types of hyperoxaluria (by limiting oxalate intake); secondary hyperoxaluria	Limited oxalate intake ^{109,196} , calcium ^{146,152} , limited fat intake ^{146,152} , cholestyramine ^{153,154} , ^a , lanthanum carbonate ¹⁵⁷ , sevelamer ¹⁵⁸	NA
Administration of oxalate-degrading microbes	Different types of hyperoxaluria	OC5 (refs. ^{161,162,197}), Nov-001 (ref. ¹⁶⁵)	<i>Lactobacillus paragasseri</i> UBLG-36 (ref. ¹⁶⁶), SYNBS802 (ref. ¹⁶⁷)
Oxalate decarboxylase supplementation	Secondary hyperoxaluria	Proprietary oxalate decarboxylase ¹⁷¹ , recombinant oxalate decarboxylase cloned from <i>Bacillus subtilis</i> ¹⁷² , ALLN-177 (refs. ^{173,174})	NA
Ensure proper folding and/or relocation of AGT	Primary hyperoxaluria type 1	Vitamin B6 (refs. ^{118–120,198,199})	NA
Protein inhibition or knockout of genes encoding oxalate-producing hepatic enzymes	Primary hyperoxaluria type 1	Lumasiran ^{179,180,182,183} , nedosiran ¹⁸⁴	CRISPR-Cas9 (refs. ^{186–188})
Inhibition of NLRP3 and pro-inflammatory cytokines	Experimental only	NA	miR-22-3p ¹⁹⁰ , CP-456773/CRID3/MCC950 (ref. ¹⁹²)

AGT, alanine-glyoxylate aminotransferase; NA, not applicable; NLRP3, NACHT, LRR and PYD domains-containing protein 3.

^aOngoing clinical trial.